

# (11) EP 1 541 197 B1

(12)

### **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:18.03.2009 Bulletin 2009/12

(51) Int Cl.: A61K 31/343 (2006.01) A61P 25/22 (2006.01)

A61K 31/4545 (2006.01) A61P 25/24 (2006.01)

(21) Application number: 04025035.9

(22) Date of filing: 21.10.2004

(54) Use of pipamperone and an SNDRI, SNRI or SSRI for the treatment of mood or anxiety disorders

Verwendung von Pipamperon und einem SNDRI, SNRI oder SSRI zur Behandlung von Stimmungsoder Angststörungen

Utilisation de pipamperone et d'un SNDRI, SNRI ou SSRI pour le traitement des troubles de l'humeur ou anxieux

(84) Designated Contracting States:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PL PT RO SE SI SK TR

(30) Priority: 02.12.2003 EP 03447279 05.01.2004 EP 04447001 18.03.2004 EP 04447066

- (43) Date of publication of application: 15.06.2005 Bulletin 2005/24
- (73) Proprietor: PharmaNeuroBoost N.V. 3570 Alken (BE)
- (72) Inventor: Buntinx, Erik 3750 Alken (BE)
- (74) Representative: De Clercq, Ann G. Y. et al De Clercq, Brants & Partners c.v. Edgard Gevaertdreef 10a 9830 Sint-Martens-Latem (BE)

(56) References cited: WO-A-98/43646 US-A- 5 762 960

DE-A-4 039 631

 VOLMAT R ET AL: "The treatment of depressions by Cledial. Evolution and clinical state and handwriting" PSYCHOLOGIE MEDICALE 1986 FRANCE, vol. 18, no. 10, 1986, pages 1615-1622, XP009028776

- SQUELART P ET AL: "Pipamperone (Dipiperon), a useful sedative neuroleptic drug in troublesome chronic psychotic patients." ACTA PSYCHIATRICA BELGICA. BELGIUM 1977 MAR-APR, vol. 77, no. 2, March 1977 (1977-03), pages 284-293, XP009028314 ISSN: 0300-8967
- KOCH H J ET AL: "Successful therapy of tardive dyskinesia in a 71-year-old woman with a combination of tetrabenazine, olanzapine and tiapride." INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. ENGLAND MAR 2003, vol. 57, no. 2, March 2003 (2003-03), pages 147-149, XP009030046 ISSN: 1368-5031
- DIEBOLD K. ET AL: "Are psychoactive-druginduced changes in plasma lipid and lipoprotein levels of significance for clinical remission in psychiatric disorders?."
   PHARMACOPSYCHIATRY, (1998) 31/2 (60-67)., 1998, XP009029360
- PERUGI G ET AL: "EFFECTIVENESS OF ADJUNCTIVE GABAPENTIN IN RESISTANT BIPOLAR DISORDER: IS IT DUE TO ANXIOUS-ALCOHOL ABUSE COMORBIDITY?" JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, WILLIAMS AND WILKINS, US, vol. 22, no. 6, 2002, pages 584-591, XP009029358 ISSN: 0271-0749
- ADLER L ET AL: "PRAXIS DER STATIONAEREN AKUTBEHANDLUNG VON MANIEN RETROSPEKTIVE VERGLEICHSUNTERSUCHUNG AN JE 100 PATIENTEN ZWEIER PSYCHIATRISCHER ZENTREN PRACTICE OF IN-PATIENT ACUTE TREATMENT OF MANIAS" FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, STUTTGART, DE, vol. 62, no. 12, 1994, pages 479-488, XP009029389 ISSN: 0720-4299

10-1-0-1

Note: Within nine months of the publication of the mention of the grant of the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- ANSOMS C ET AL: "Sleep disorders in patients with severe mental depression: double-blind placebo-controlled evaluation of the value of pipamperone (Dipiperon)." ACTA PSYCHIATRICA SCANDINAVICA. FEB 1977, vol. 55, no. 2, February 1977 (1977-02), pages 116-122, XP009041169 ISSN: 0001-690X
- LEYSEN J E ET AL: "RECEPTOR INTERACTIONS OF NEW ANTIPSYCHOTICS: RELATION TO PHARMACODYNAMIC AND CLINICAL EFFECTS" INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, MARTIN DUNITZ, LONDON, GB, vol. 2, no. 1, 1998, pages S03-S17, XP001009585 ISSN: 1365-1501
- DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1996, SCHOTTE A ET AL: "Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding" XP002290498 Database accession no. PREV199698829913 & PSYCHOPHARMACOLOGY, vol. 124, no. 1-2, 1996, pages 57-73, ISSN: 0033-3158
- VANHOENACKER P ET AL: "EFFICIENT EXPRESSION OF THE HUMAN DOPAMINE D4.2 RECEPTOR: POSITIVE INFLUENCE OF PIPAMPERONE ON EXPRESSION LEVELS" ABSTRACTS OF THE SOCIETY FOR NEUROSCIENCE, SOCIETY FOR NEUROSCIENCE, WASHINGTON, DC, US, vol. 26, no. 1/2, 2000, page 1, XP001181469 ISSN: 0190-5295
- VIJVER VAN DE D A M C ET AL:
  "ANTIPSYCHOTICS AND PARKINSON'S
  DISEASE: ASSOCIATION WITH DISEASE AND
  DRUG CHOICE DURING THE FIRST 5 YEARS OF
  ANTIPARKINSONIAN DRUG TREATMENT"
  EUROPEAN JOURNAL OF CLINICAL
  PHARMACOLOGY, SPRINGER VERLAG, DE, vol.
  58, no. 7, 2002, pages 157-161, XP009033980
  ISSN: 0031-6970
- ENGELBORGHS S ET AL: "AMINO ACIDS AND BIOGENIC AMINES IN CEREBROSPINAL FLUID OF PATIENTS WITH PARKINSON'S DISEASE" NEUROCHEMICAL RESEARCH, PLENUM PRESS, NEW YORK, US, vol. 28, no. 8, August 2003 (2003-08), pages 1145-1150, XP009031514 ISSN: 0364-3190
- DATABASE EMBASE [Online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1999, ETCHEPAREBORDA M C: "Neurocognitive and pharmacological approach to specific learning disorders" XP002312308 Database accession no. EMB-2000050033 & REVISTA DE NEUROLOGIA 1999 SPAIN, vol. 28, no. SUPPL. 2, 1999, pages S81-S93, ISSN: 0210-0010

- WIRZ-JUSTICE A ET AL: "HALOPERIDOL DISRUPTS, CLOZAPINE REINSTATES THE CIRCADIAN REST-ACTIVITY CYCLE IN A PATIENT WITH EARLY-ONSET ALZHEIMER DISEASE" ALZHEIMER DISEASE AND ASSOCIATED DISORDERS, RAVEN PRESS, NEW YORK, NY, US, vol. 14, no. 4, 2000, pages 212-215, XP009029353 ISSN: 0893-0341
- FAHS H ET AL: "THYMOREGULATEURS DANS L'AGITATION ET LES TROUBLES DU COMPORTEMENT CHEZ LE SUJET DEMENT A PROPOS DE HUIT CAS ANTICONVULSIVANTS AND AGGRESSIVE BEHAVIORS IN ALZHEIMER'S DISEASE. EIGHT CASES REPORTS" ENCEPHALE, PARIS, FR, vol. 25, no. 2, 1999, pages 169-174, XP009039295 ISSN: 0013-7006
- GRÖZINGER M ET AL: "Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine." PHARMACOPSYCHIATRY.
   GERMANY JAN 2003, vol. 36, no. 1, January 2003 (2003-01), pages 3-6, XP009029363 ISSN: 0176-3679
- WERTH ESTHER ET AL: "Decline in long-term circadian rest-activity cycle organization in a patient with dementia." JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY. 2002 SPRING, vol. 15, no. 1, April 2002 (2002-04), pages 55-59, XP009042127 ISSN: 0891-9887
- STAHL STEPHEN M ET AL: "Examination of nighttime sleep-related problems during doubleblind, placebo-controlled trials of galantamine in patients with Alzheimer's disease." CURRENT MEDICAL RESEARCH AND OPINION. APR 2004, vol. 20, no. 4, April 2004 (2004-04), pages 517-524, XP009041652 ISSN: 0300-7995
- DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1995, MELTZER HERBERT Y ET AL: "Plasma clozapine levels and the treatment of L-DOPAinduced psychosis in Parkinson's disease. A high potency effect of clozapine" XP002290499 Database accession no. PREV199598192811 & NEUROPSYCHOPHARMACOLOGY, vol. 12, no. 1, 1995, pages 39-45, ISSN: 0893-133X
- MUENCHAU A ET AL: "PHARMACOLOGICAL TREATMENT OF PARKINSON'S DISEASE" POSTGRADUATE MEDICAL JOURNAL, MCMILLAN PRESS, BASINGSTOKE, GB, vol. 76, no. 900, October 2000 (2000-10), pages 602-610, XP009034316 ISSN: 0032-5473
- FALTRACO F ET AL: "AKTUELLE THERAPIEMOEGLICHKEITEN DER ALZHEIMER DEMENZ CURRENT THERAPEUTICAL STRATEGIES IN DEMENTIA" NEUROLOGIE UND REHABILITATION, BONN, DE, vol. 9, no. 1, 2003, pages 15-22, XP009041267 ISSN: 0947-2177

 MONTGOMERY S.A.; ANDERSEN H.F.: 'Escitalopram versus venlafaxine XR in the treatment of depression' INTERNATIONAL

CLINICAL PHARMACOLOGY vol. 21, no. 5, 2006, pages 297 - 309

- KHAN ARIF; WARNER HEATHER A.; BROWN WALTERA.: 'Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: An analysis of the Food and Drug Administration database' ARCHIVES OF GENERAL PSYCHIATRY vol. 57, no. 4, 2000, pages 311 - 317
- MOORE NICHOLAS; VERDOUX HÉLÈNE; FANTINO BRUNO: 'Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder' INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY vol. 20, no. 3, 2005, pages 131 - 137
- WIELING W. ET AL: 'INITIAL ORTHOSTATIC HYPOTENSION AS A CAUSE OF RECURRENT SYNCOPE: A CASE REPORT' CLINICAL AUTONOMIC RESEARCH vol. 11, no. 4, 2001, page 270, XP009039296
- FOUKS D. ET AL: 'TRAITEMENT DES TROUBLES CARACTERIELS PAR UNE NOUVELLE BUTYROPHENOME: LE R. 3345 OU PIPAMPERONE/TREATMENT OF CHARACTER DISORDERS WITH A NEW BUTYROPHENONE: R. 3345 OR PIPAMPERONE' ANNALES MEDICO-PSYCHOLOGIQUES vol. 124, no. 5, 1966, pages 677 681, XP009028328
- "Pipamperone dichlorhydrate"[Online] 2000, pages 1-4, Retrieved from the Internet: URL:http: //www.biam2.org/www/Sub2783.html> [retrieved on 2007]
- 'Médicaments psychotropes: posologies chez l'enfant et l'adolescent', [Online] 2001, pages 1 3 Retrieved from the Internet: <URL:http://www.adiph.org/pic/pedia-neurole ptiques.pdf> [retrieved on 2007-00-00]
- HEISER P.; REMSCHMIDT H.: 'SELECTIVE SEROTONIN REUPTAKE INHIBITORS AND NEWER ANTIDEPRESSIVE SUBSTANCES IN CHILD AND ADOLESCENT PSYCHIATRY. DIE SELEKTIVEN SEROTONIN-WIEDERAUFNAHMEHEMMER UND DIE NEUEREN ANTIDEPRESSIVA-SUBSTANZEN IN DER KINDER- UND JUGENDPSYCHIATRIE' ZEITSCHRIFT FUER KINDER- UND JUGENDPSYCHOTHERAPIE vol. 30, no. 3, 2002, pages 173-183, XP009076880
- CARLIER P.R. ET AL: 'Synthesis of a Potent Wide-Spectrum Serotonin-, Norepinephrine-, Dopamine-Reuptake Inhibitor (SNDRI) and a Species-Selective Dopamine-Reuptake Inhibitor Based on the Gamma-Amino Alcohol Functional Group' BIOORGANIC & MEDICINAL CHEMISTRY LETTERS vol. 8, no. 5, 1998, pages 487 - 492
- MAINA GIUSEPPE ET AL: 'ANTIPSYCHOTIC AUGMENTATION FOR TREATMENT RESISTANT OBSESSIVE-COMPULSIVE DISORDER: WHAT IF ANTIPSYCHOTIC IS DISCONTINUED?' INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY vol. 18, no. 1, 01 January 2003, pages 23 - 28, XP009078546

#### Remarks:

The file contains technical information submitted after the application was filed and not included in this specification

P 1 541 197 B1

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

#### Description

### Field of the invention

[0001] The invention relates to the field of neuropsychiatry. More specifically, the invention relates to the use of compounds, which have D4 and 5-HT2A antagonist, inverse agonist or partial agonist activity, for the preparation of medicaments:

#### Background of the invention

10

45

5

[0002] Conventionally, mental disorders are divided into types based on criteria sets with defining features. DSM-IV (American Psychiatric Association, (1993 - ISBN 0 - 89042 - 061 - 0)) is the in the art well-known golden standard of such a categorical classification. In DSM-IV, there is no assumption that each category of mental disorder is a completely discrete entity with absolute boundaries dividing it from other mental disorders or from no mental disorder. There is also no assumption that all individuals described as having the same mental disorder are alike in all important ways. Individuals sharing a diagnosis are likely to be heterogeneous even in regard to the defining features of the diagnosis. Thus, the categorical defined mental disorders as mood and anxiety disorders are having an external and even internal variable co-incidence of symptoms concerning e.g. mood, anxiety, perception, feeding, somatic sensations, sexual functions, sleep, cognitive functioning, impulse control, attention, substance use, personality, bereavement, identity, phase of life, abuse or neglect and other aspects of behavior.

[0003] In a <u>dimensional system</u>, clinical presentations are classified based on quantification of attributes i.e. dysfunctions rather than the assignment to categories and works best in describing phenomena that are distributed continuously and that do not have clear boundaries.

[0004] Emotion dysregulation is known as such an attribution or dysfunction that plays an important role in the development and course of mental disorders (Gross, J. J. & Munoz, R. F., 1995, Emotion regulation and mental health, Clinical Psychology: Science and Practice, 2, 151-164; Mennin, D.S., Heimberg, R. G., Turk, C. L. & Fresco, D. M., 2002. Applying an emotion regulation framework to integrative approaches to generalized anxiety disorder, Clinical Psychology: Science and Practice, 9, 85-90; Linehan, M. M., 1993, Cognitive-behavioral treatment of borderline personality disorder. New York, The Guilford Press, Gratz, K. L., Roemer, L., 2001 & 2004, Multidimensional assessment of emotion regulation and dysregulation: development, factor structure, and initial validation of the Difficulties in Emotion Regulation Scale, Annual meeting of the Association for Advancement of Behavior Therapy, Nov. 2001 & Journal of Psychopathology and Behavioral Assessment, Vol. 26, No. 1, March 2004) besides behavioural and cognitive dysfunctions. D4 dopamine receptors (D4DR), almost exclusively present in the mesocortical and mesolimbic systems (O'Malley, K. L., Harmon, S., Tang, L., Todd, R. D., The rat dopamine D4 receptor: sequence, gene structure, and demonstration of expression in the cardiovascular system, New Biol., 4, 137-46, 1992), are in the art known as modulators of emotion and cognition. D4DR agonistic activity gives a behavioural sensitisation; D4DR antagonistic activity leads to an emotion modulation (Svensson, T. H., Mathé, A. A., Monoaminergic Transmitter Systems, Biological Psychiatry (eds. D'Haenen, H., et al.), 45-66, 2002, John Wiley & Sons, Ltd.). Data demonstrate that agonism of the dopamine D4 receptors play an important role in the induction of behavioral sensitization to amphetamine and accompanying adaptations in pre- and postsynaptic neural systems associated with the mesolimbocortical dopamine projections (D. L. Feldpausch et al.; The Journal of Pharmacology and Experimental Therapeutics Vol. 286, Issue 1, 497-508, July 1998).

[0005] Results suggest that the antagonisms of cortical D2 dopamine receptors are a common target of traditional and atypical antipsychotics for therapeutic action. Higher *in vivo* binding to the D2 receptors in the cortex than in the basal ganglia is suggested as an indicator of favorable profile for a putative antipsychotic compound (X. Xiberas and J.L. Martinot; The British Journal of Psychiatry (2001) 179: 503-508). Results show that dopamine D4 receptor antagonism in the brain does not result in the same neurochemical consequences (increased dopamine metabolism or hyperprolactinemia) observed with typical neuroleptics (Smita Patel et al., The Journal of Pharmacology and Experimental Therapeutics Vol. 283, Issue 2, 636-647,1997). The selective D4 dopamine receptor antagonist L-745,870 was ineffective as an antipsychotic for the treatment of neuroleptic responsive patients with acute schizophrenia (Kramer, M.S. et al., Arch. Gen. Psychiatry 1997 Dec; 54(12):1080).

[0006] Finally, in the biological system, mental disorders are defined on other levels of abstraction than in the categorical and dimensional system. Structural pathology (e.g. amyloid plaques in Alzheimer Disease), etiology (e.g. HIV Dementia) and deviance from a physiological norm (e.g. reduced cerebral blood flow) are often used as indicative biological markers for a mental disorder. The underlying dysregulation of various neurotransmittor systems (glutaminergic, GABAergic, cholinergic, monoaminergic (noradrenergic, dopaminergic, serotonergic), etc.) is the in the art used model for the explanation of the biological determinants of the clinical presentation of mental disturbances. It is known that the Serotonin 2A Receptor (5-HT2A receptor) - which is widespread in the Central Nervous System (CNS) - has a regulating role on the dysregulation of various neuro-transmittor systems. 5-HT2A agonism gives several behavioural disturbances; 5-

HT2A antagonism leads to a governance of mood, social behaviour, anxiety, cognitive function, stress, sleep functions, nociception, sexual functions, feeding and other aspects of behaviour (J.E. Leysen (2004) 5-HT2 Receptors; Current Drug Targets - CNS & Neurological Disorders, 2004, 3, 11-26).

[0007] Dysregulation of the HPA axis (hypothalamic - pituitary - adrenal axis) has frequently been reported in patients with psychiatric disorders, and is among the most robustly demonstrated neurobiological changes among psychiatric patients (D.A. Gutman and C.B. Nemeroff, Neuroendocrinology, Biological Psychiatry (eds. D'Haenen, H., et al), 99, 2002, John Wiley & Sons, Ltd). The resulting elevated plasma cortisol concentrations leads to an enhanced binding of serotonin for the 5-HT2A receptor (E. A. Young, Mineralocorticoid Receptor Function in Major Depression, Arch Gen Psychiatry, Jan 2003; 60: 24 - 28) and thus agonism.

[0008] Additionally 5-HT2A antagonism gives a des-inhibiting of the inhibitory effect of the 5-HT2A receptor on (i) the 5-HT1A receptor stimulation by serotonin (S. M. Stahl, Newer Antidepressants and Mood Stabilizers, Essential Psychopharmacology, 265, University Press; 2 edition (June 15, 2000); ISBN: 0521646154) and on (ii) the dopamine release in the mesocortical systems (S. M. Stahl, Classical Antidepressants, Serotonin Selective and Noradrenargic Reuptake Inhibitors, Essential Psychopharmacology, 233, University Press; 2 edition (June 15, 2000); ISBN: 0521646154).

[0009] Clinical or real effectiveness of psychopharma is very rare via common pooping-out; many treatment-refractory patients and up to half of patients fail to attain remission (S. M. Stahl, Essential Psychopharmacology, Depression and Bipolar Disorders, 151, University Press; 2 edition (June 15, 2000); ISBN: 0521646154). Implications of not attaining remission for Mental Disorders are increased relapse rates, continuing functional impairment and increased suicide rate (S. M. Stahl, Essential Psychopharmacology, Depression and Bipolar Disorders, 152, University Press; 2 edition (June 15, 2000); ISBN: 0521646154). Clinical causes of not attaining remission by the Current Psychopharmacological Compounds are inadequate early treatment, underlying emotion dysregulation (affecting instability - hypersensitivity - hyperaesthesia - dissociative phenomena, etc.) and competitive antagonism. There is thus a growing need for a more efficient therapy and more efficient, selective and efficacious medicaments for treating mental disorders.

#### Summary of the invention

25

[0010] The present invention describes the use of compounds and pharmaceutical compositions having D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic activity for the treatment of the underlying emotion dysregulation of mental disorders (e.g. affecting instability - hypersensitivity - hyperaesthesia - dissociative phenomena - etc.) and to methods entailing administering to a patient diagnosed as having a mental disorder a pharmaceutical composition containing (i) compounds having specific high selective D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic activity and (ii) a known medicinal compound and/or compositions of compounds. The combined D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic effects may reside within the same chemical or biological compound.

[0011] Taken into account the above mentioned (i) rare clinical or real effectiveness of psycho tropics, (ii) the governance of the features and dysfunctions responsible - in a variable coincidentally - for the clinical state of the mental disorders by D4 dopamine receptor (D4DR) and 2A serotonin receptor (5-HT2A) antagonism and (iii) the fact that 5-HT2A antagonism gives a des-inhibiting of the inhibitory effect of the 5-HT2A receptor on (a) the 5-HT1A receptor stimulation by serotonin and on (b) the dopamine release in the mesocortical systems, the present invention relates to the use of a compound for the preparation of a medicament for treating a disease or disorder with an underlying emotion dysregulation, characterised in that said compound has (i) a selective affinity for the Dopamine-4 (D4) receptor with a pKi value equal to or higher than 8 towards the D4 receptor and less than 8 towards other Dopamine receptors, and (ii) a selective affinity for the 5-HT2A receptor with a pKi value equal to or higher than 8 towards the 5-HT2A receptor and less than 8 towards other 5-HT receptors and wherein said compound is administered to a patient in a dose ranging between 5 and 15 mg of the active ingredient. According to the present invention said compound is pipamperon.

[0012] According to a first embodiment, the present invention relates to the use of pipamperone or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating a mood disorder or anxiety disorder, wherein said pipamperone or a pharmaceutically acceptable salt is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient, and wherein a second compound is to be administered simultaneously with, separate from or sequential to said pipamperone to augment the therapeutic effect of said second compound, said second compound is selected from the group consisting of: selective serotonin, nor-adrenaline and dopamine re-uptake inhibitor (SNDRI), selective serotonin and nor-adrenaline re-uptake inhibitor (SNRI) and selective serotonin re-uptake inhibitor (SSRI).

[0013] More particularly, wherein said pipamperone is to be administered daily at least one day before administering said second compound.

[0014] More preferably the present invention relates to the use of pipamperone or a pharmaceutically acceptable salt thereof as defined above, wherein said second compound is a selective serotonin, noradrenaline and dopamine reuptake inhibitor (SNDRI) compound.

[0015] More preferably said selective serotonin, nor-adrenalins and dopamine re-uptake inhibitor (SNDRI) compound

is selected from the group consisting of NS 2330, McN 5652, DOV 216,303 and DOV 21,947, or a pharmaceutically acceptable salt thereof.

[0016] According to a further embodiment, the present invention relates to a pharmaceutical composition comprising (a) pipamperone, and a selective serotonin, nor-adrenaline and dopamine re-uptake inhibitor (SNDRI) compound, as a combined preparation for simultaneous, separate or sequential use for treating the underlying emotion dysregulation of mental disease or disorder which is chosen from the group consisting of mood disorders and anxiety disorders, wherein said pipamperone is to be administered to a patient in a daily dose of between 5 and 15 mg of the active ingredient.

[0017] Preferably, said selective serotonin, nor-adrenaline and dopamine re-uptake inhibitor (SNDRI) compound is selected from the group consisting of NS 2330, McN 5652, DOV 216,303 and DOV 21,947, or a pharmaceutically acceptable salt thereof

[0018] Preferably, the use of pipamperone or a pharmaceutically acceptable salt thereof is as defined above, wherein said second compound is a selective serotonin, and nor-adrenaline re-uptake inhibitor (SNRI) compound.

[0019] More preferably, the invention relates to the use of pipamperone or a pharmaceutically acceptable salt thereof as defined above, wherein said selective serotonin and nor-adrenatine re-uptake inhibitor (SNRI) compound is selected from the group consisting of venlafaxine, tomoxetine, tandamine, talsupram, talopram, nefazodone, milnacipran, LY 113.821, duloxetine, desvenlafaxine and amoxapine, or a pharmaceutically acceptable salt thereof.

[0020] For instance, the invention relates to the use of pipamperone or a pharmaceutically acceptable salt thereof as defined above, wherein said venlafaxine, or a pharmaceutically acceptable salt thereof, is to be administered in a daily dose ranging between 75 and 300 mg of the active ingredient.

[0021] Also, the invention relates to the use of pipamperone or a pharmaceutically acceptable salt thereof as defined above, wherein said tomoxetine, or a pharmaceutically acceptable salt thereof, is to be administered in a daily dose ranging between 0.475 and 3.8 mg/kg of the active ingredient

[0022] Also the invention relates to the use of pipamperone or a pharmaceutically acceptable salt thereof as defined above, wherein said milnacipran, or a pharmaceutically acceptable salt thereof, is to be administered in a daily dose ranging between 50 and 200 mg of the active ingredient.

[0023] Further, the invention relates to the use of pipamperone or a pharmaceutically acceptable salt thereof as defined above, wherein said duloxetine, or a pharmaceutically acceptable salt thereof, is to be administered in a daily dose ranging between 40 and 60 mg of the active ingredient.

[0024] According to a further embodiment, the present invention relates to a pharmaceutical composition comprising (a) pipamperone and (b) a selective serotonin and nor-adrenaline re-uptake inhibitor (SNRI) compound as a combined preparation for simultaneous, separate or sequential use for treating the underlying emotion dysregulation of mental disease or disorder which is chosen from the group to be administered to a patient in a daily consisting of mood disorders and anxiety disorders, wherein said pipamperone is dose of between 5 and 15 mg of the active ingredient.

30

[0025] Preferably, the said selective serotonin and nor-adrenaline re-uptake inhibitor (SNRI) compound is selected from the group consisting of venlafaxine, tomoxetine, tandamine, talsupram, talopram, nefazodond, milnacipran, LY 113.821, duloxetine, desvenlafaxine and amoxapine, or a pharmaceutically acceptable salt thereof.

[0026] Also, the invention relates to the pharmaceutical composition as defined above, wherein said venlafaxine, or a pharmaceutically acceptable salt thereof, provided in a unitary dose of between 75 and 300 mg of the active ingredient. [0027] Also, the invention relates to the pharmaceutical composition as defined above, wherein said tomoxetine, or a pharmaceutically acceptable salt thereof, is provided in a unitary dose of between 0.475 and 3.8 mg/kg of the active ingredient.

[0028] Also, the invention relates to the pharmaceutical composition as defined above, wherein said milnacipran, or a pharmaceutically acceptable salt thereof, is provided in a unitary dose of between 50 and 200 mg of the active ingredient. [0029] Further, the invention relates to the pharmaceutical composition as defined above, wherein said duloxetine, or a pharmaceutically acceptable salt thereof, is provided in a unitary dose of between 40 and 60 mg of the active ingredient. [0030] The invention also relates to the use of pipamperone or a pharmaceutical acceptable salt thereof as defined above, wherein said second compound is a selective serotonin reuptake inhibitor (SSRI) compound.

[0031] Preferably the invention relates to the use of pipamperone or a pharmaceutically acceptable salt thereof as defined above, wherein said selective serotonin re-uptake inhibitor (SSRI) compound is selected from the group consisting of YM 992, VPI-013 (OPC-14523), sertraline, paroxetine, LY 214.281, LU AA 21-004, Lu 35-138, litoxetine, ifoxetine, fluvoxamine (controlled release formulation), fluvoxamine, fluoxetine, femoxetine, escitalopram, EMD 68843, cyanodothepine, citalopram, venlafaxine, milnacipran, duloxetine, cericlamine and ademethionine preferably s-adenosylmethionine, or a pharmaceutically acceptable salt thereof.

[0032] Preferably, the invention relates to the use of pipamperone or a pharmaceutically acceptable salt thereof as defined above, wherein said selective serotonin re-uptake inhibitor (SSRI) compound is fluvoxamine (controlled release formulation), or a pharmaceutically acceptable salt thereof, is to be administered in a daily dose ranging between 100 and 300 mg of the active ingredient.

[0033] Preferably, the invention relates to the use of pipamperone or a pharmaceutically acceptable salt thereof as

defined above, wherein said selective serotonin re-uptake inhibitor (SSRI) compound is escitalopram, and is to be administered in a daily dose ranging between 10 and 20 mg of the active ingredient.

[0034] Preferably, the invention relates to the use of pipamperone or a pharmaceutically acceptable salt thereof as defined above, wherein said selective serotonin re-uptake inhibitor (SSRI) compound is citalopram, and is to be administered in a daily dose ranging between 10 and 40 mg of the active ingredient.

[0035] Further, the invention relates to a pharmaceutical composition comprising (a) pipamperone and (b) a selective serotonin re-uptake inhibitor (SSRI) compound as a combined preparation for simultaneous, separate or sequential use for treating the underlying emotion dysregulation of mental disease or disorder which is chosen from the group consisting of mood disorders and anxiety disorders, wherein, said pipamperone is to be administered to a patient in a daily dose of between 5 and 15 mg of the active ingredient.

[0036] Further the invention relates to the pharmaceutical composition as defined above, wherein said selective serotonin re-uptake inhibitor (SSRI) compound is selected from the group consisting of YM 992, VPI-013 (also known as OPC-14523), sertraline, paroxetine, LY 214.281, LU AA 21-004, Lu 35-138, litoxetine, ifoxetine, fluvoxamine (controller release formulation), fluvoxamine, fluoxetine, femoxetine, escitalopram, EMD 68843, cyanodothepine, citalopram, venlafaxine, milnacipran, duloxetine, cericlamine and ademethionine (preferably s-adenosylmethionine), or a pharmaceutically acceptable salt thereof.

[0037] Further the invention relates to the pharmaceutical composition as defined above, wherein said fluvoxamine (controlled release formulation), or a pharmaceutically acceptable salt thereof, is provided in a unitary dose of between 100 and 300 mg of the active ingredient.

[0038] Further, the invention relates to the pharmaceutical composition as defined above, wherein said escitalopram, or a pharmaceutically acceptable salt thereof, is provided in a unitary dose of between 10 and 20 mg of the active ingredient.

[0039] Further, the invention relates to the pharmaceutical composition as defined above, wherein said citalopram, or a pharmaceutically acceptable salt thereof, is provided in a unitary dose of between 10 and 40 mg of the active ingredient.

[0040] According to a further embodiment the invention relates to the use of a first compound as defined above for the preparation of a medicament for treating a mental disease or disorder with an underlying emotion dysregulation whereby a second compound is administered simultaneously with, separate from or sequential to said first compound to augment the therapeutic effect of said second compound on said disease, or to provide a faster onset of the therapeutic effect of said second compound on said disease.

[0041] The mental diseases or disorders characterized by an underlying emotion dysregulation can be grouped into subclasses as follows: (i) non-cognitive mental disorders comprising mood disorders, anxiety disorders, psychotic disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sexual and gender identity disorders, sleep disorders, adjustment disorders, impulse control disorders, pervasive development disorders, attention-deficit disorders, disruptive behaviour disorders, substance-related disorders, personality disorders, psychological factors affecting medical conditions, malingering, antisocial behaviour, bereavement, occupational problems, identity problem, phase of life problem, academic problem and problems related to abuse or neglect; (ii) cognitive diseases comprising delirium, Alzheimer Disease, substance-related persisting dementia, vascular dementia, dementia due to HIV disease, dementia due to head trauma, dementia due to Parkinson Disease, dementia due to Huntington Disease, dementia due to Pick Disease, dementia due to Creutzfeldt-Jacob Disease, amnestic disorders due to a general medical condition, substance-induced persisting amnestic disorder, mild cognitive impairment disorder, other cognitive disorders; (iii) pain disorders; and (iv) Parkinson Disease.

[0042] In a preferred embodiment, the first compound is administered daily at least one day before administering said second compound.

45 [0043] Preferably, said second compound is characterized by the physiological property of influencing positively the activity of the Central Nervous System.

### Detailed description of the invention

[0044] The present inventors surprisingly found that compounds which have a high selective affinity towards the 5-HT2A receptor and which, at the same time have a high selective affinity towards the dopamine-4 (D4) receptor show an improved effect in treating underlying emotion dysregulation of mental disorders.

[0045] The compounds according to the invention may be chemical or biological in nature, or may be chemically synthesised. Preferably, the compounds of the invention are provided as a pharmaceutically acceptable salt.

[0046] One example of such a compound which has both a selective affinity for the 5-HT2A receptor with a pKi value equal to or higher than 8 towards the 5-HT2A receptor and less than 8 towards other 5HT receptors, and a selective affinity for the D4 receptor with a pKi value equal to or higher than 8 towards the D4 receptor and less than 8 towards other dopamine receptors is pipamperon. Pipamperon is the conventional name given for the compound of the formula

1'-[3-(p-Fluorobenzoyl)propyl]-[1,4'-bipiperidine]-4'-carboxamide. Pipamperon is also the active ingredient of for instance the commercially available Dipiperon (Janssen, Cilag B.V).

[0047] Further, the present inventors surprisingly found that the dosage of active ingredient for pipamperon in treatment (in combination therapy as described in more detail further) could be very low compared to conventionally used dosages. Preferred dosages which, according to the invention, have been shown to be effective for treating these mental disorders, range between 5 and 15 mg per day or between 5 and 10 mg per day. More preferably, dosages of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 mg per day are used in treatment of the diseases of the invention. In conventional pipamperon treatment, the active ingredient is available in tablets of 40 mg per tablet or in solutions of 2 mg per drop. Conventional usage of high doses ranging from 40 to 360 mg is prescribed. For instance, for children up to the age of 14, doses corresponding with 2 to 6 mg per kg body weight are conventionally prescribed. The high selective affinity of pipamperon towards the 5-HT2A receptor and the D4 receptor is reflected in the low dosage which is needed for the treatment of the mental diseases listed below and also contributes to the efficacy of the treatment.

[0048] Mental disorders such as depression are commonly treated with serotonin re-uptake inhibitors. Unfortunately, however, these compounds can give rise to side effects in use. Moreover, a substantial problem in most treatment of mental disorders is the non-response to selective serotonin re-uptake inhibitors (SSRIs). Also the onset of the therapeutic effect can be delayed undesirable.

[0049] A problem to be solved by the present invention is thus the provision of a more efficient therapy and efficient, highly selective and efficacious medicaments for treating mental disorders.

[0050] The inventors found that, for instance, the non-response to selective serotonin re-uptake inhibitors (SSRIs) in depression may be declared by (partial) inhibition of the 5-HT1A stimulation via 5-HT2A stimulation. Des-inhibition thereof via 5-HT2A antagonism seems to be an answer to this problem.

[0051] The present inventors found that a simultaneous or foregoing treatment with a compound having a high selective 5-HT2A antagonist, inverse agonist or partial agonist activity, could lead to a greater response towards, for instance, SSRIs. However, not all compounds exhibiting 5-HT2A antagonism are useful: competition between 5-HT2A stimulation via serotonin and 5-HT2A antagonism via the compound could be responsible for the lack of more efficacy of compounds which have both a selective serotonin re-uptake inhibitory and 5-HT2A antagonist profile, such as trazodone and nefazodone.

[0052] The present inventors further surprisingly found that a simultaneous or foregoing treatment with a compound having a high selective D4 antagonist, inverse agonist or partial agonist activity in combination with a compound having a high selective 5-HT2A antagonist, inverse agonist or partial agonist activity could lead to a greater response towards, for instance, SSRIs

[0053] In this invention, the term "antagonist" refers to an interaction between chemicals in which one partially or completely inhibits the effect of the other, in particular agents having high affinity for a given receptor, but which do not activate this receptor.

[0054] In this invention, the term "inverse agonist" refers to a ligand which produces an effect opposite to that of the agonist by occupying the same receptor.

[0055] In this invention, the term "agonist" relates to an agent which both binds to a receptor and has an intrinsic effect.

[0056] In this invention, the term "partial agonist" relates to an agent with lower intrinsic activity than a full agonist, and which produces a lower maximum effect.

40 [0057] The present inventors found that a compound which binds to the 5-HT2A receptor with a pKi of at least 8 but for which the binding affinity, i.e. pKi, towards other 5HT receptors is less than 8 in combination with a high selective affinity for the D4 receptor, i.e. which bind to the D4 receptor with a pKi of at least 8 but for which the binding affinity, i.e. pKi, towards other dopamine receptors is less than 8 also show such an improved effect in treatment. These effects, i.e. D4 antagonism, inverse agonism or partial agonism and 5-HT2A antagonism, inverse agonism or partial agonism, may reside in the same compound.

[0058] The term "other 5HT receptors" as used herein relate to for instance 5-HT1 receptors (e.g. 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-HT1 F), 5-HT2B, 5-HT2C, 5-HT6 (rat) and 5-HT7 (rat).

[0059] By the expression "selective affinity for the 5-HT2A receptor" is meant that the receptor has a higher affinity for the 5-HT2A receptor than for other 5-HT receptors.

[0060] The expression "selective affinity for the D4 receptor" means that the receptor has a higher affinity for the dopamine D4 receptor than for other dopamine receptors.

[0061] The term "other dopamine receptors" are, for instance, D1, D2 and D3 dopamine receptors.

[0062] pKi values of test compounds for dopamine receptors as well as 5-HT2A receptors can be measured using commonly known assays.

[0063] Compounds which have a selective affinity for the D4 receptor preferably have a pKi value equal to or higher than 8 towards the D4 receptor and less than 8 towards other dopamine receptors.

[0064] Preferably, the compounds of the invention which have a selective affinity for the 5-HT2A receptor (or the D4 receptor), are compounds which have a pKi value equal to or higher than 8 towards the 5-HT2A receptor and the D4

receptor, and less than 8 towards other 5-HT receptors or dopamine receptors, respectively, as can be measured, for instance by methods known in the art. For instance, the "NIMH Psychoactive Drug Screening Program (PDSP)" K<sub>i</sub> database (http://kidb.cwru.edu/nimh/5htp.php), is a unique resource in the public domain which provides information on the abilities of drugs to interact with an expanding number of molecular targets. The PDSP K<sub>i</sub> database serves as a data warehouse for published and internally-derived pKi, or affinity, values for a large number of drugs and drug candidates at an expanding number of G-protein coupled receptors, ion channels, transporters and enzymes. The PDSP internet site also provides for commonly used protocols and assays for measuring pKi values of 5-HT and dopamine receptors. [0065] A preferred example of a compound which has both a selective affinity for the 5-HT2A receptor with a pKi value equal to or higher than 8 towards other 5-HT receptors, and a selective affinity for the D4 receptor with a pKi value equal to or higher than 8 towards the D4 receptor and less than 8 towards other Dopamine receptors and which is therefore useful in a combination therapy is pipamperon.

5

10

30

35

45

50

[0066] Table 1 illustrates the selective affinity of for instance pipamperon for the 5-HT2A and for the D4 receptor. In addition, Table 1 also illustrates the low or absence of affinity of pipamperon for other receptors such as the adrenergic receptors Alpha 1A, Alpha 2A, Alpha 2B, Alpha 2C, Beta 1, Beta 2, and the histamine receptor H1. As such, treating patients with pipamperon will provide for less side effects which otherwise result from simultaneous stimulation of other receptors. Therefore, and according to preferred embodiments, useful compounds according to the invention not only have a selective 5-HT2A and/or D4 affinity but also a low affinity for other receptors such as the adrenergic and histamine receptors.

[0067] The low dosage which can be used in pipamperon treatment, as already described earlier, contributes to the high selective affinity of the compound towards the 5-HT2A receptor and the D4 receptor and therefore also to the efficacy of the treatment.

[0068] The mental diseases or disorders characterized by an underlying emotion dysregulation can be grouped into subclasses as follows: (i) the non-cognitive mental disorders comprising mood disorders, anxiety disorders, psychotic disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sexual and gender identity disorders, sleep disorders, adjustment disorders, impulse control disorders, pervasive development disorders, attention-deficit disorders, disruptive behaviour disorders, substance-related disorders, personality disorders, psychological factors affecting medical conditions, malingering, antisocial behaviour, bereavement, occupational problems, identity problem, phase of life problem, academic problem and problems related to abuse or neglect; (ii) cognitive diseases comprising delirium, Alzheimer Disease, substance-related persisting dementia, vascular dementia, dementia due to HIV disease, dementia due to head trauma, dementia due to Parkinson Disease, dementia due to Huntington Disease, dementia due to Pick Disease, dementia due to Creutzfedt-Jacob Disease, amnestic disorders due to a general medical condition, substance-induced persisting amnestic disorder, mild cognitive impairment disorder, other cognitive disorders; (iii) the pain disorders; and (iv) Parkinson Disease. In Table 5, this classification has been used for summarizing the diseases and disorders relative to known psychotropics. In Table 6, an overview of pharmacological grouping is provided, indicating the pharmalogical profile numbering, the pharmalogical profile, the main disease or disorder indication(s), the name of the compound, the dose range, and the company producing or selling said compound.

[0069] These diseases and their diagnosis are very clearly defined in the "Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)" published by the American Psychiatric Association. This manual sets forth diagnostic criteria, descriptions and other information to guide the classification and diagnosis of mental disorders and is commonly used in the field of neuropsychiatry. It is for instance available on the internet under: <a href="http://www.behavenet.com/capsules/disorders/dsm4tr.htm">http://www.behavenet.com/capsules/dsm4tr.htm</a>.

[0070] The expression "non-cognitive diseases or disorders" used in some of the embodiments of the invention comprises the following group of diseases or disorders: mood disorders, anxiety disorders, psychotic disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sexual and gender identity disorders, sleep disorders, adjustment disorders, impulse control disorders, pervasive development disorders, attention-deficit disorders, disruptive behaviour disorders, substance-related disorders, personality disorders, psychological factors affecting medical conditions, malingering, antisocial behaviour, bereavement, occupational problems, identity problem, phase of life problem, academic problem and problems related to abuse or neglect.

[0071] The expression "(related) cognitive diseases or disorders" according to the invention comprises, the following group of diseases or disorders: delirium (F05), dementia (such as Alzheimer Disease (F00), vascular dementia (F01), dementia due to other general medical conditions (HIV disease (F02.4), head trauma (F06.8), Parkinson Disease (F02.3), Huntington Disease (F02.2), Pick Disease (F02.0), Creutzfeldt-Jacob Disease (F02.1) and other (F02.8)), substance-induced persisting dementia (F1x.6)), amnestic disorders due to a general medical condition (F06.8) or a substance-induced persisting amnestic disorder (F1x.6), mild cognitive impairment disorder (F06.7) and other cognitive disorders (F04). The above list of diseases is provided by way of example and is not intended to limit the invention.

[0072] For instance, Alzheimer Disease is a degenerative brain disease of unknown cause that is the most common

form of dementia. Alzheimer Disease usually starts in late middle age or in old age as a memory loss for recent events spreading to memories for more distant events and progresses over the course of five to ten years to a profound intellectual decline characterized by dementia and personal helplessness. The disease is marked histologically by the degeneration of brain neurons especially in the cerebral cortex and by the presence of neurofibrillary tangles and plaques containing beta-amyloid. Because dopamine receptor D4 (DRD4) antagonism can inhibit the behavioral disturbances merely aggression and confusion - caused by the degeneration of dopamine D2 receptors (Esiri, M.M., The basis for behavioural disturbances in dementia, J. Neurol. Neurosurg. Psychiatry, 1996; 61(2):127-130.2) accompanied with Alzheimer disease and 5-HT2A antagonism has an important boosting effect towards the effect of cholinesterase inhibitors such as used in the treatment by facilitating the affected dopamine release in the mesocortical dopamine pathways, a high selective D4/5-HT2A-antagonist would be a more preferable compound to combine with a cholinesterase inhibitor since this avoids the counteracting effect of the in the art used SDAs on the cognitive functioning by its dopamine receptor D2-antagonism.

5

25

[0073] These diseases and their diagnoses are very clearly defined in the "International Statistical Classification of Diseases and Related Health Problems, 1989 Revision, Geneva, World Health Organization, 1992 (ICD-10). This manual sets forth diagnostic criteria, descriptions and other information to guide the classification and diagnosis of neurodegenerative disorders and is commonly used in the field of neurology. According to the ICD-10 classification, the cognitive disorders are classified under several classes of disorders, i.e. dispersed under categories F00 to F19 (see above: respective classification between parentheses). Following the DSM classification, however, they are grouped in one class of diseases or disorders.

[0074] The terms "treatment", "treating" as used herein include amelioration or elimination of a developed mental disease or condition once it has been established or alleviation of the characteristic symptoms of such disease or condition. As used herein these terms also encompass, depending on the condition of the patient, preventing the onset of a disease or condition or of symptoms associated with a disease or condition, including reducing the severity of a disease or condition or symptoms associated therewith prior to affliction with said disease or condition. Such prevention or reduction prior to affliction refers to administration of the compound or composition of the invention to a patient that is not at the time of administration afflicted with the disease or condition. "Preventing" also encompasses preventing the recurrence or relapse-prevention of a disease or condition or of symptoms associated therewith, for instance after a period of improvement. It should be clear that mental conditions may be responsible for physical complaints. In this respect, the term "treating" also includes prevention of a physical disease or condition or amelioration or elimination of the developed physical disease or condition once it has been established or alleviation of the characteristic symptoms of such conditions.

[0075] As used herein, the term "medicament" also encompasses the terms "drug", "therapeutic", "potion" or other terms which are used in the field of medicine to indicate a preparation with therapeutic or prophylactic effect.

[0076] The present inventors not only found that the selective 5-HT2A and D4 antagonists, inverse agonists or partial agonists have an effect in augmenting the therapeutic effect or in providing a faster onset of the therapeutic effect of a diversity of other pharmaceutical compounds, i.e. also named "second compounds" in the present invention, in the treatment of specific diseases or disorders.

[0077] Second compounds useful according to the invention are SSRI, SNRI and SNDRI compounds provided in Table 5. It should be clear that in the present invention, pipamperon is never to be seen as a "second compound".

[0078] According to the invention, it thus has been found that the compounds having a selective 5-HT2A and D4 antagonist, inverse agonist or partial agonist activity as described above are useful for augmenting the therapeutic effect of a second compound on a disease.

[0079] According to another embodiment of the invention, it has also been found that the compounds having a selective 5-HT2A and D4 antagonist, inverse agonist or partial agonism, activity as described above are useful for providing a faster onset of the therapeutic effect of a second compound on a disease.

[0080] From the above it should be clear that the selective 5-HT2A and D4 antagonist, inverse agonist or partial agonist is also named 'the first compound' in the embodiments of the invention.

[0081] According to the invention, when the 5-HT2A and D4 antagonist, inverse agonist or partial agonist activity reside in separate compounds, the term "composition" may be used. Compositions of the invention comprise a first element having (i) a selective affinity for the D4 receptor with a pKi value equal to or higher than 8 towards the D4 receptor and less than 8 towards other dopamine receptors, and a second element having (ii) a selective affinity for the 5-HT2A receptor with a pKi value equal to or higher than 8 towards the 5-HT2A receptor and less than 8 towards other 5-HT receptors.

[0082] The expression "the 5-HT2A and D4 antagonist, inverse agonist or partial agonist" is used herein to indicate a single compound having both activities or to indicate the composition comprising the activities in separate elements. [0083] It should be clear that when, in the present invention, a composition of separate elements is used instead of a single compound, this composition of separate elements may be used in combination with another, i.e. a second, compound to augment the therapeutic effect of the other, i.e. the second, compound on the same or another disease.

[0084] When the 5-HT2A and D4 antagonist, inverse agonist or partial agonist or the composition comprising both elements and the second compound are administered simultaneously, the compounds or active ingredients may be present in a single pharmaceutical composition or formulation. Alternatively the compounds or active ingredients are administered in separate pharmaceutical compositions or formulations for simultaneous or separate use. The invention thus also relates to pharmaceutical compositions comprising pipamperon and a second compound of the invention and to the uses of these pharmaceutical compositions.

5

10

15

30

45

[0085] When the 5-HT2A and D4 antagonist, inverse agonist or partial agonist or the composition comprising both elements of the invention are administered prior to the second compound as defined, the 5-HT2A and D4 antagonist, inverse agonist or partial agonist or the composition comprising both elements is administered at least during 1 day prior to said second compound. Preferably, the 5-HT2A and D4 antagonist, inverse agonist or partial agonist (e.g. pipamperon) or the composition comprising both elements is administered for at least 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 days prior to the administration of the second compound. Preferably, the 5-HT2A and D4 antagonist, inverse agonist or partial agonist (e.g. pipamperon) or the composition comprising both elements is administered for at least 2, 3, 4 or 5 weeks prior to the administration of the second compound, or even for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 months prior to the administration of the second compound.

[0086] According to a preferred embodiment of the invention, the above described compounds or the composition comprising both elements having a 5-HT2A and D4 antagonist, inverse agonist or partial agonist activity are useful for augmenting the therapeutic effect of citalogram or for providing a faster onset of the therapeutic effect of citalogram.

[0087] Citalopram or citalopram hydrobromide is a selective serotonin (5-hydroxytryptamine / 5-HT) re-uptake inhibitor (SSRI) and is the conventional name given for the compound of the formula (RS)-1-[3-(dimethylamino)propyl]-1-(p-flurophenyl)-5-phthalancarbonitrile hydro-bromide.

[0088] According to an embodiment, a daily dose of active ingredient of SSRI, preferably citalopram, ranges between 10 and 40 mg per day. Preferably, daily doses of active ingredient ranging between 20 and 30 mg per day are administered. More preferably, a daily dose of 10, 15, 20, 25, 30, 35 or 40 mg per day is administered.

[0089] According to another preferred embodiment of the invention, the above described compounds or the composition comprising both elements having a 5-HT2A and D4 antagonist, inverse agonist or partial agonist activity are useful for augmenting the therapeutic effect of citalopram or for providing a faster onset of the therapeutic effect of fluvoxamine. [0090] Fluvoxamine or fluvoxamine maleate (luvox, fevarin) is a selective serotonin (5-HT) reuptake inhibitor (SSRI) belonging to a new chemical series, the 2-aminoethyl oxime ethers of aralkylketones. It is chemically unrelated to other SSRIs and clomipramine. It is chemically designated as 5-methoxy-4'-(trifluoromethyl) valerophenone (E)-O-(2-aminoethyl) oxime maleate (1:1).

[0091] According to an embodiment, a daily dose of active ingredient of fluvoxamine maleate ranges between 100 and 300 mg per day. Preferably, daily doses of active ingredient ranging between 150 and 200 mg per day are administered. More preferably, a daily dose of 100, 150, 200, 250 or 300 mg per day is administered.

[0092] Most of the second compounds herein described are known in the art and may be used in doses according to the supplier's or physician's prescription, or may be used according to specific embodiments described herein.

[0093] The present invention also encompasses the use of these second compounds, administered in the form of a pharmaceutically acceptable salt in admixture with a suitable pharmaceutically acceptable excipient.

[0094] To prepare the pharmaceutical compositions, comprising the compounds or the combination of the first and second compound described herein, an effective amount of the active ingredients, in acid or base addition salt form or base form, is combined in admixture with a pharmaceutically acceptable carrier, which can take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, for administration orally, nasal, rectally, percutaneously or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included.

[0095] The pharmaceutical compounds for treatment are intended for parenteral, topical, oral or local administration and generally comprise a pharmaceutically acceptable carrier and an amount of the active ingredient sufficient to reverse or prevent the bad effects of mental disorders. The carrier may be any of those conventionally used and is limited only by chemico-physical considerations, such as solubility and lack of reactivity with the compound, and by the route of administration.

[0096] Examples of pharmaceutically acceptable acid addition salts for use in the present inventive pharmaceutical composition include those derived from mineral acids, such as hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric and sulfuric acids, and organic acids, such as tartaric, acetic, citric, malic, lactic, fumaric, benzoic, glycolic, gluconic,

succinic, p-toluenesulphonic acids, and arylsulphonic, for example.

5

10

30

40

[0097] The pharmaceutically acceptable excipients described herein, for example, vehicles, adjuvants, carriers or diluents, are well-known to those who are skilled in the art and are readily available to the public. It is preferred that the pharmaceutically acceptable carrier be one that is chemically inert to the active compounds and one that has no detrimental side effects or toxicity under the conditions of use.

[0098] The following formulations for oral, aerosol, parenteral, subcutaneous, intravenous, intramuscular, interperitoneal, rectal, and vaginal administration are merely exemplary and are in no way limiting. Overall, the requirements for effective pharmaceutical carriers for parenteral compositions are well known to those of ordinary skill in the art. See Pharmaceutics and Pharmacy Practice, J.B. Lippincott Company, Philadelphia, PA, Banker and Chalmers, eds., pages 238-250, (1982), and ASHP Handbook on Injectable Drugs, Toissel, 4th ed., pages 622-630 (1986). Topical formulations, including those that are useful for transdermal drug release, are well-known to those of skill in the art and are suitable in the context of the present invention for application to skin.

[0099] Formulations suitable for oral administration require extra considerations considering the nature of the compounds and the possible breakdown thereof if such compounds are administered orally without protecting them from the digestive secretions of the gastrointestinal tract. Such a formulation can consist of (a) liquid solutions, such as an effective amount of the compound dissolved in diluents, such as water, saline, or orange juice; (b) capsules, sachets, tablets, lozenges, and troches, each containing a predetermined amount of the active ingredient, as solids or granules; (c) powders; (d) suspensions in an appropriate liquid; and (e) suitable emulsions. Liquid formulations may include diluents. such as water and alcohols, for example, ethanol, benzyl alcohol, and the polyethylene alcohols, either with or without the addition of a pharmaceutically acceptable surfactant, suspending agent, or emulsifying agent. Capsule forms can be of the ordinary hard- or soft-shelled gelatin type containing, for example, surfactants, lubricants, and inert fillers, such as lactose, sucrose, calcium phosphate, and corn starch. Tablet forms can include one or more of lactose, sucrose, mannitol, corn starch, potato starch, alginic acid, microcrystalline cellulose, acacia, gelatin, guar gum, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, calcium stearate, zinc stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, disintegrating agents, moistening agents, preservatives, flavoring agents, and pharmacologically compatible excipients. Lozenge forms can comprise the active ingredient in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions, gels, containing, in addition to the active ingredient, such excipients as are known in the art.

[0100] The compounds of the present invention, alone or in combination with other suitable components, can be made into aerosol formulations to be administered via inhalation. For aerosol administration, the compounds are preferably supplied in finely divided form along with a surfactant and propellant. Typical percentages of compounds are 0.01 %-20% by weight, preferably 1%-10%. The surfactant must, of course, be nontoxic, and preferably soluble in the propellant. Representative of such agents are the esters or partial esters of fatty acids containing from 6 to 22 carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride. Mixed esters, such as mixed or natural glycerides may be employed. The surfactant may constitute 0.1%-20% by weight of the compounds, preferably 0.25-5%. The balance of the compounds is ordinarily propellant. A carrier can also be included as desired, e.g., lecithin for intranasal delivery. These aerosol formulations can be placed into acceptable pressurized propellants, such as dichlorodifluoromethane, propane, nitrogen. They also may be formulated as pharmaceuticals for non-pressured preparations, such as in a nebulizer or an atomizer. Such spray formulations may be used to spray mucosa.

[0101] It will be understood that, apart from daily doses, the compounds can be administered by other schedules. For instance, the present invention also contemplates depot injection, in which a long acting form of the active compound is injected into the body, such as the muscles. From there the active compound slowly enters the rest of the body, so one injection can last from 1 to 4 weeks or even multiple months. Other form of dosage administrations relate to "once-a-week" pills, in which the ingredient is slowly released over a period of a week, and slow-realese patches, e.g. a CDS (Continuous Delivery System), or Once-a-Day Transdermal Patches.

[0102] It should be clear that the compounds and compositions described herein are useful for treating any patient in need thereof. As used herein the term "patient" is not restricted to humans but also to other mammals, for instance, domestic animals which may also suffer from any form of a mental disease or disorder described herein.

[0103] The second compounds of the invention can be further grouped according to their pharmacological profile, which is summarized in Table 6.

[0104] The present invention is now described in more detail by the following embodiments. The compounds belonging to different pharmacological profiles can be further grouped according to their action on the same pathway or system as follows.

### 90: combination therapy with a selective SNDRI compound

**[0105]** The mental disorders which can be treated using compounds having a high selective affinity for the 5-HT2A and D4 receptor, for instance pipamperon, in a combination therapy with a selective serotonin, nor-adrenaline and dopamine re-uptake inhibitor (SNDRI) compound, are chosen from the group of diseases or disorders consisting of mood disorders, anxiety disorders.

[0106] The present invention thus relates to the use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders consisting of mood disorders, anxiety disorders, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a selective serotonin, nor-adrenaline and dopamine re-uptake inhibitor (SNDRI) compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said selective serotonin, nor-adrenaline and dopamine re-uptake inhibitor (SNDRI) compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

[0107] According to a preferred embodiment, the invention relates to the uses as described above, wherein said selective serotonin, nor-adrenaline and dopamine re-uptake inhibitor (SNDRI) compound is selected from the group consisting of NS 2330; McN 5652; DOV 216,303 and DOV 21,947; more preferably NS 2330 or DOV 216,303; or a pharmaceutically acceptable salt thereof.

[0108] The invention also relates to a pharmaceutical composition comprising (a) pipamperon, and (b) a selective serotonin, nor-adrenaline and dopamine re-uptake inhibitor (SNDRI) compound, preferably selected from the group consisting of NS 2330; McN 5652; DOV 216,303 and DOV 21,947, more preferably NS 2330 or DOV 216,303, or a pharmaceutically acceptable salt thereof, as a combined preparation for simultaneous, separate or sequential use for treating the underlying emotion dysregulation of mental disease or disorder which is chosen from the group consisting of mood disorders, anxiety disorders.

#### 91: combination therapy with a selective SNRI compound

20

30

35

**[0109]** The mental disorders which can be treated using compounds having a high selective affinity for the 5-HT2A and D4 receptor, for instance pipamperon, in a combination therapy with a selective serotonin and nor-adrenaline reuptake inhibitor (SNRI) compound, are chosen from the group of diseases or disorders consisting of mood disorders, anxiety disorders.

[0110] The present invention thus relates to the use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders consisting of mood disorders, anxiety disorders, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a selective serotonin and nor-adrenaline re-uptake inhibitor (SNRI) compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said selective serotonin and nor-adrenaline re-uptake inhibitor (SNRI) compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.

[0111] According to a preferred embodiment, the invention relates to the uses as described above, wherein said selective serotonin and nor-adrenaline re-uptake inhibitor (SNRI) compound is selected from the group consisting of venlafaxine, tomoxetine, tandamine, talsupram, talopram, nefazodone, milnacipran, LY 113.821, duloxetine, desvenlafaxine and amoxapine, or a pharmaceutically acceptable salt thereof. Even more preferably, said selective serotonin and nor-adrenaline re-uptake inhibitor (SNRI) compound is chosen from the group consisting of venlafaxine, tomoxetine, milnacipran, duloxetine and desvenlafaxine, or a pharmaceutically acceptable salt thereof. More preferably, said selective serotonin and nor-adrenaline re-uptake inhibitor (SNRI) compound is venlafaxine and is to be administered in a daily dose ranging between 75 and 300 mg of the active ingredient. More preferably, said selective serotonin and nor-adrenaline re-uptake inhibitor (SNRI) compound is tomoxetine and is to be administered in a daily dose ranging between 0.475 and 3.8 mg/kg of the active ingredient. More preferably, said selective serotonin and nor-adrenaline re-uptake inhibitor (SNRI) compound is duloxetine and is to be administered in a daily dose ranging between 50 and 200 mg of the active ingredient. More preferably, said selective serotonin and nor-adrenaline re-uptake inhibitor (SNRI) compound is duloxetine and is to be administered in a daily dose ranging between 40 and 60 mg of the active ingredient.

[0112] The invention also relates to a pharmaceutical composition comprising (a) pipamperon, and (b) a selective serotonin and nor-adrenaline re-uptake inhibitor (SNRI) compound, preferably selected from the group consisting of venlafaxine, tomoxetine, tandamine, talsupram, talopram, nefazodone, milnacipran, LY 113.821, duloxetine, desvenlafaxine and amoxapine, or a pharmaceutically acceptable salt thereof, as a combined preparation for simultaneous, separate or sequential use for treating the underlying emotion dysregulation of mental disease or disorder which is chosen from the group consisting of mood disorders, anxiety disorders,

- [0113] The invention also relates to a pharmaceutical composition as described above wherein pipamperon is provided in a unitary dose of between 5 and 15 mg of the active ingredient and wherein said selective serotonin and nor-adrenaline re-uptake inhibitor (SNRI) compound is venlafaxine, preferably provided in a unitary dose of between between 75 and 300 mg of the active ingredient.
- [0114] The invention also relates to a pharmaceutical composition as described above wherein pipamperon is provided in a unitary dose of between 5 and 15 mg of the active ingredient and wherein said selective serotonin and nor-adrenaline re-uptake inhibitor (SNRI) compound is tomoxetine, preferably provided in a unitary dose of between 0.475 and 3.8 mg/kg of the active ingredient.
- [0115] The invention also relates to a pharmaceutical composition as described above wherein pipamperon is provided in a unitary dose of between 5 and 15 mg of the active ingredient and wherein said selective serotonin and nor-adrenaline re-uptake inhibitor (SNRI) compound is milnacipran, preferably provided in a unitary dose of between 50 and 200 mg of the active ingredient.
  - [0116] The invention also relates to a pharmaceutical composition as described above wherein pipamperon is provided in a unitary dose of between 5 and 15 mg of the active ingredient and wherein said selective serotonin and nor-adrenaline re-uptake inhibitor (SNRI) compound is duloxetine, preferably provided in a unitary dose of between 40 and 60 mg of the active ingredient.

#### 92: combination therapy with a selective serotonin re-uptake inhibitor (SSRI) compound

30

- [0117] The mental disorders which can be treated using compounds having a high selective affinity for the 5-HT2A and D4 receptor, for instance pipamperon, in a combination therapy with a selective serotonin re-uptake inhibitor (SSRI) compound, are chosen from the group of diseases or disorders consisting of mood disorders, anxiety disorders.
- [0118] The present invention thus relates to the use of pipamperon or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders consisting of mood disorders, anxiety disorders, characterized in that pipamperon or said pharmaceutically acceptable salt thereof is administered simultaneously with, separate from or prior to the administration of a selective serotonin re-uptake inhibitor (SSRI) compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said selective serotonin re-uptake inhibitor (SSRI) compound, further characterized in that pipamperon is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient.
- [0119] According to a preferred embodiment, the invention relates to the uses as described above, wherein said selective serotonin re-uptake inhibitor (SSRI) compound is selected from the group consisting of YM 992, VPI-013 (also known as OPC-14523), sertraline, paroxetine, LY 214.281, LU AA 21-004, Lu 35-138, litoxetine, ifoxetine, fluvoxamine (controlled release formulation), fluvoxamine, fluoxetine, femoxetine, escitalopram, EMD 68843, cyanodothepine, citalopram, venlafaxine, milnacipran, duloxetine, cericlamine and ademethionine (preferably s-adenosylmethionine), or a pharmaceutically acceptable salt thereof. Even more preferably, said selective serotonin re-uptake inhibitor (SSRI) compound is chosen from the group consisting of litoxetine, fluvoxamine (controlled release formulation) and escitalopram, or a pharmaceutically acceptable salt thereof.
- [0120] More preferably, said selective serotonin re-uptake inhibitor (SSRI) compound is fluvoxamine (controlled release formulation) and is to be administered in a daily dose ranging between 100 and 300 mg of the active ingredient. More preferably, said selective serotonin re-uptake inhibitor (SSRI) compound is escitalopram and is to be administered in a daily dose ranging between 10 and 20 mg of the active ingredient. More preferably, said selective serotonin re-uptake inhibitor (SSRI) compound is citalopram and is to be administered in a daily dose ranging between 10 and 40 mg of the active ingredient.
- [0121] The invention also relates to a pharmaceutical composition comprising (a) pipamperon, and (b) a selective serotonin re-uptake inhibitor (SSRI) compound, preferably selected from the group consisting of YM 992, VPI-013 (also known as OPC-14523), sertraline, paroxetine, LY 214.281, LU AA 21-004, Lu 35-138, litoxetine, ifoxetine, fluvoxamine (controlled release formulation), fluvoxamine, fluoxetine, femoxetine, escitalopram, EMD 68843, cyanodothepine, citalopram, venlafaxine, milnacipran, duloxetine, cericlamine and ademethionine (preferably s-adenosylmethionine), or a pharmaceutically acceptable salt thereof, as a combined preparation for simultaneous, separate or sequential use for treating the underlying emotion dysregulation of mental disease or disorder which is chosen from the group consisting of mood disorders, anxiety disorders.
  - [0122] The invention also relates to a pharmaceutical composition as described above wherein pipamperon is provided in a unitary dose of between 5 and 15 mg of the active ingredient and wherein said selective serotonin re-uptake inhibitor (SSRI) compound is fluvoxamine (controlled release formulation), preferably provided in a unitary dose of between between 100 and 300 mg of the active ingredient.
  - [0123] The invention also relates to a pharmaceutical composition as described above wherein pipamperon is provided in a unitary dose of between 5 and 15 mg of the active ingredient and wherein said selective serotonin re-uptake inhibitor

(SSRI) compound is escitalopram, preferably provided in a unitary dose of between 10 and 20 mg of the active ingredient. [0124] The invention also relates to a pharmaceutical composition as described above wherein pipamperon is provided in a unitary dose of between 5 and 15 mg of the active ingredient and wherein said selective serotonin re-uptake inhibitor (SSRI) compound is citalopram, preferably provided in a unitary dose of between 10 and 40 mg of the active ingredient. [0125] Citalopram or citalopram hydrobromide is a selective serotonin (5-hydroxytryptamine / 5-HT) re-uptake inhibitor (SSRI) and is the conventional name given for the compound of the formula (RS)-1-[3-(dimethylamino)propyl]-1-(p-flurophenyl)-5-phthalancarbonitrile-hydro-bromide. According to an embodiment, a daily doses of active ingredient of SSRI, preferably citalopram, ranges between 10 and 40 mg per day. Preferably, daily doses of active ingredient ranging between 20 and 30 mg per day are administered. More preferably, a daily dose of 10, 15, 20, 25, 30, 35 or 40 mg per day is administered.

[0126] Fluvoxamine or fluvoxamine maleate (luvox, fevarin) is a selective serotonin (5-HT) reuptake inhibitor (SSRI) belonging to a new chemical series, the 2-aminoethyl oxime ethers of aralkylketones. It is chemically unrelated to other SSRIs and clomipramine. It is chemically designated as 5-methoxy-4'-(trifluoromethyl) valerophenone (E)-O-(2-aminoethyl) oxime maleate (1:1).

[0127] According to an embodiment, a daily dose of active ingredient of fluvoxamine in a controlled release mode ranges between 100 and 300 mg per day. Preferably, daily doses of active ingredient ranging between 150 and 200 mg per day are administered in a controlled release mode. More preferably, a daily dose of 100, 150, 200, 250 or 300 mg per day is administered by controlled release.

[0128] The invention, now being generally described, will be more readily understood by reference to the following tables and examples.

### Short description of the Tables and Figures

#### [0129]

25

15

20

- **Table 1**: In Table 1, the pKi values of test compounds are given for each of the dopamine receptors, 5HT receptors, adrenergic receptors and the histamine1 receptor.
- Table 2: Set-up of a clinical trial comprising for treatment groups.

30

- **Table 3**: Overview of a placebo, active and period controlled clinical trial in a fore-going pipamperon citalopram treatment in Major Depressive Disorder.
- Table 4: POC process for major depressive disorder.

35

Table 5: Summary of diseases and disorders relative to known psycho-tropics.

40

- **Table 6:** Overview of Pharmacological grouping, indicating pharmacological profile numbering (column 2), pharmacological profile (column 3), main indication(s) (column 4), name of the compound (column 4), the dose range (column 5), and the company producing or selling said compound (column 6). Compounds indicated by hatching are preferred.
- Figure 1: Add-on treatment with pipamperon after treatment with citalogram.

45

**Figure 2**: HDRS-17 change from baseline: combo treatment pipamperon as add-on - citalopram vs SNRI (duloxetine) in Major Depression.

--

**Figure 3**: Remission rates (HDRS-17 <=7): combo treatment pipamperon as add-on - citalopram vs SNRI (venla-faxine) vs SSRIs vs placebo in Major Depression.

50

**Figure 4**: Fore-going treatment during 1-5 days with pipamperon followed with the combination treatment of pipamperon and citalopram.

55

**Figure 5**: HDRS-17 change from baseline: combo treatment pipamperon - citalopram with a fore-going treatment of 4 days with pipamperon vs SNRI (duloxetine) in Major Depression.

Figure 6: Remission rates (HDRS-17 <=7): combo pipamperon - citalopram with a fore-going treatment of 4 days with pipamperon vs SNRI (venlafaxine) in Major Depression.

	Figure 7: Fore-going treatment during 6-8 days with pipamperon followed with the combination treatment of pipamperon and citalopram.
5	Figure 8: HDRS-17 change from baseline: combo treatment pipamperon - citalopram with a fore-going treatment of 7 days with pipamperon vs SNRI (duloxetine) in Major Depression.
	Figure 9: Fore-going and add-on treatment with pipamperon in MDD.
10	Figure 10: HDRS-17 change from baseline: fore-going and add-on treatment with pipamperon and citalopram in comparison with the SNRI duloxetine in Major Depression.
	Figure 11: Remission rates (HDRS-17 <=7): fore-going and add-on treatment with pipamperon and citalopram in comparison with the SNRI venlafaxine in Major Depression.
15	Figure 12: Y-BOCS total score: fore-going and add-on treatment with pipamperon and citalopram in comparison with the SSRI fluvoxamine in OCD.
20	Figure 13: Y-BOCS obsession score: fore-going and add-on treatment with pipamperon and citalopram in comparison with the SSRI fluvoxamine in OCD.
20	Figure 14: Y-BOCS compulsion score: fore-going and add-on treatment with pipamperon and citalopram in comparison with the SSRI fluvoxamine in OCD.
25	Figure 15: CGI-severity score: fore-going and add-on treatment with pipamperon and citalogram in comparison with the SSRI in panic disorder.
30	
35	
40	
45	
50	
55	

	IH	8	ž	0	8	6	0	0	0	0	6-7	0	6-7	0	٥	7-8	0	2,8	0	0	8-9	٥	7-8	\$
5	Betal	8	8	0	8	8	8	0	٥	0	8	٥	8	0	0	3	0	â	0		9	8	9	\$
	Betal	8	Ŷ	0	9	8	\$	٥	0	٥	8	0	Ŷ	0	0	6.7	0	8	0	0	9>	9	9	9>
10	Alpha2C	7-8	6.7	8.9	6-7	7-8	6-7	0	0	0	6-7	0	\$	0	0	7-8	0	6-8	0	0	2-9	۷6	7-8	2-9
	82sdqlA	×	8.9	8-9	6-7	2-8	7-8	0	0	0	6-7	0	6-7	0	0	7-8	0	6.8	0	0	7-8	6-8	7-8	7-8
15	ASedqlA	6-8	5.	6-8	2-9	7-8	6-7	6-7	9>	9>	6-7	8	9>	6-7	\$	6-7	0	2.8	Ŷ	\$	\$	6-8	2-9	6-7
	AladqlA	6	0	6-7	7-8	8-9	8-9	۷,	7-8	\$	۷,	9>	6-8	6<	9	0	8	8	6-7	2-9	7-8	6-7	6-8	0
<u>.</u> . :	5HT <sub>7</sub> TH2	×	0	0	6-7	7-8	7-8	0	0	0	0	0	6-7	0	0	0	0	•	0	0	2-9	0	6-8	
20	5HT <sub>6</sub> rat	ž	0	0	7-8	7-8	7-8	0	0	0	0	0	9>	0	0	0	0	0	0	0	0	0	7-8	0
	SHT <sub>2C</sub>	X	0	9>	8-9	7-8	7-8	6-7	\$	\$	6-8	7-8	8	6-8	9	0	7-8	7-8	7-8	9>	2-9	9>	6-8	0
25	SHT <sub>2B</sub>	6<	0	0	6-8	8.9	6.8	٥	0	8	0	0	8	٥	0	0	0	0	6-7	6-7	6-7	0	6.8	9
	. ATTE	6 <u>X</u>	6-8	رزو	6-8	8-9	Ž,	6-8	8-9	ونؤي	8	8	/ <u>/</u> 29)	8.	(£=£9)	. 49.	٥<	>9	(E):-(E)	(0):	(j) e(t)	Ģ	×	8.9
30	31TH2	0	0	0	6-7	5	0	0	0	٥	6.7	0	٧	0	0	0	0	9>	0	0	8	•	0	8
	31TH2	7-8	6-7	0	۶	6.7	۰	•	٥	-	2	0	Ÿ	0	0	\$	0	\$	0	0	٥	-	6.7	8
35	alTH2	6-8	7-8	٧	6-7	6.7	•	0	۰	۶	7-8	0	8	٥	0	8	0	6-7	6-7	٧	٧	2,8	6.8	6-7
	81THS	6-8	7.8	8	6.7	6.7	٥	٥	0	\$	7-8	0	6-7	٥	9	\$	0	6-8	6-7	Ŷ	Ŷ	6.7	۸	6-3
40	AITHS	6-8	6-7	6-7	8	6.7	8-9	7-8	8	6-7	6-7	9	8	8-9	8	7-8	7.8	6.7	8	۶	6.7	7-8	8.9	\$
	েত্র	6-8	JX.	(E)	W.S.	. E.	eg G	8-9	٤.	(9)	95F	e E.	8.9	8-9		8-9	8-9	8.9	*3	. (9)	یه	ç.		8-9
45	D3	8-9	6.8	\$	2-8	3	2.8	5	હ	Š	6-8 0-8	8	8	8.9	8.9		8.9	7-8	Š	7-8	5	\$	7-8	6.7
	DZ	8-9	6.8	8	2,8	5	2.8	2.8	6.7	7-8	8	٧	۸	8-9	6-8 8-0	٨	۶,	6-8	78	<u>8</u>	6.7	6.7	6-8	6-7
	ıα	62	-	0	28	8	9	%	6	٧	-28 -28	6.7	6.8	7-8	8	0	7.8	7.8	6-7	6.7	٤	9	6-8	
os Table 1		ORG\$222	Zotepine	Fluparoxan	Olanzapine	Clozapine	S16924	S18327	Amperozide	GGR218231	Sertindole	MDL100,907	Halopcridol	Tiospirone	Raciopride	Fluspirilene	Ocaperidone	Risperidone	S33084	L741626	Scroquel	Yohimbine	Ziprasidone	Pipamperon
55	L	0	7	正	0	ण	<u>∞</u>	S	₹	ŏΙ	<u>ا تن</u>	Σ	ヹ	ij	۲۲	ī	ŏ	₽]	S	긔	Ϋ́	۲	<u>  73</u>	<u>آ</u>

Table 2

5		(bliA)	@//\D		Ä	A	W	₩			×	×	×	×		×	×			
	d.	S) S	lw.		W	æ	W	∜			×	Γ					×		1	
10	FOLLOW-UP PHASE	MIN	Mi 12		Q. COLOR			200000000000000000000000000000000000000			×	×	×	×		×	×	T		
	FOI	WIG	(M)								×						×		1	
15		Sia	MB			9	ŀ				×						×			
		W14	W224							::	×	×	×	×		×	×			
		Wil3	)    w20	:					Ŀ		×		Ŀ		L		×			
20		Wis			Ŀ				. ::		×		4.		L		×			
	EXTENSION PHASE***	18	)   W12		١.				ų, i	r ·	×		•	Ŀ		Ŀ	×	_		
25	NOIS	M.	3. Will	1. 1.		i, E	; i			_	×	Ц		٠	_	Ľ	×	Ŀ		
	XTEN	\$\partial \partial \part	5. W.B.	电	1.	<u>.</u> :	11:				×		::		-		<b>×</b> .	-		
30		\$\$\frac{1}{2}\$	W.C	17 Fg							×					:	×	L		
		<b>№</b> 9w	W3 IN						1		X	4	2			-	×.	٠.		
		Me SA						:			×					-	×	_		
35		W DA	W		<u>ر</u>			$\exists$			×						×	Н		
		N S	<u></u>		旨	<u>ූ</u>		<b>23</b>			×		;; ; ,	:	:.	-	×			
40				:.					$\overline{\cdot}$								.:			7/17
	<b>.</b>		00 00		9	<b>13</b> )	<u>න</u>	: 0			×		 ?	٠			×			A/010
	ACUTE PHASE**		3 D7	·								7		_	-	Н			C+PLC	D. 2(01 C. DID/4
45	CUTE	il A li	रुखास क्यांकाम्ब		ď	<b>9</b> 5	⊌	≪		×	×	×	×	×	×	×	×		A: PLC	0.0
	¥		धाकी	- Group	M	<b>党</b>	<b>@</b>	9		ij		딿	.			ue				
50		Sin	# Week # Month		Active / Da	Active / DA	Active "DO	dive / DO		Conse	ř.	s/Wei	او	إي	Exam	s Scre	****	0	men:	
		SIIW	9 / We	ATTIVITE				8		Informed Consent	NECT	Vital Signs / Weigh	LAB	ECG	Phys Exam	Alc/Drugs Screen	CGI-S****	Q-LES-Q****	Treatment regimen:	
55					rigide Php.	Trients (Phys	وتعمله إياف	Granp Ple-		Ē		K			İ	₹		ď	reatme	
55	<b></b>	121212		PUNK C				<u> </u>									_	ئــ	Ţ	

A: PLC + PLC B: 2x(PLC+PIP(4mg))/d

C: 2x(CIT(10mg)+PIP(4mg))/d D: 2x(CIT(10mg)+PLC)/d

\*Neuronal E-Clinical Trial = Vesalius Expert Development for this Trial which includes the bottom-up measurement of: \*\*Entering Acute Phase: only NON-placebo responders as defined by the DSM-IV criteria of efficacy

<sup>\*\*\*</sup>Entering Extension Phase: only remittors as defined by the DSM-IV criteria of efficacy

<sup>\*\*\*\*</sup>CGI-S: Clinical Global Impressions-Improvement Scale

<sup>•••••</sup>Q-LES-Q: Quality of Life, Enjoyment and Satisfaction Questionnaire

Table 3

							දිගු	<b>U</b> 0	ಚ	Т	Т	Γ	<u> </u>		Г	Γ		П
5				PHASE	ela Me	225	ાહિ-ટીનિ દુનાઉ-દુના		නිබ්යානිශ්		-	*					×	×
10				FOLLOW-UP PHASE					Sales Sales			×					×	
					Will	2011					×	×	*	×	×	×	×	×
	DER				SON WAS	SYM	1	_[_		1	×	×		L			×	×
15	SOF			3S	Wile		27.01				Ľ	×				Ц	×	×
	/E DI			NPMA	BUA	7 N					*	×	×	×	×	×	×	×
	SSIV			E XTENSION PHASE	WIB					Ţ	×	×					×	×
	PRE			EXTE	. Aug				1		×	×	×	×	×	×	×	×
20	R DE	O B 7			Was	Wite Wish Was					×	×				П	×	×
	A YO.	ROLI			ew.					1	×	×	×	×	×	×	*	×
	IN W	ONT			80	3	П	Ī		4	×	×				П	×	×
25	ENT	DE C			<b>3</b>					1	×	×				П	×	×
	ATM	RIOI	CLINICAL TRIAL		AN AN					T	×	×			×		×	×
	TRE	3d O	AL T		® &					Ţ	×	×					×	٦
	RAM	E AN	INIC		SA W	200				Ι	×	×					×	×
30	OPF	STIVE	70		\$ &		9			:	×	×					×	×
35	FOREGOING PIPAMPERON - CITALOPRAM TREATMENT IN MAYOR DEPRESSIVE DISORDER :	a placebo, active and periode controlled			89 E	3					×	x					×	×
40	FOREGOING			ACUTE PHASE"	Emireske Em		Zyven (Gelen lennen myd	zakenintumentajarentajaren daga en			×	×	×				×	×
45					W) Sereen mans 07		SHOOTER	$\Box$	PALCONY RICK	*	×	×	×	×	×	×	×	×
50					VISIUS	COURT CONTRACTOR	Pho Advoluery 4	Alp = Adiva# @apy@ Ala = Adiva#@ay@	MEGREGO	formed Consent	NECT*	al Signs / Weight	ZA8	9	Phys Exam	Ic/Orugs Screen	SIDO	OHES-O

55

\*Neuronal E-Clinical Trial = Vesalius Expert Development for this Trial which includes the bottom-up measurement of:

In and arctusioncrateria

Functional status evaluation

Medical history

(Pre-Tureau Institute)

(Pre-Tureau Institute)

Medical resource utulisation

Pre-trial & Concomittant medication

Drug administration

(Seriucs) Adverse events

Admission to the acute and extension phase of treatment

Right flow of the trial

"Entering Acute Phase; only NON-placebo responders as defined by the DSM-IV criteria of efficacy

\*\*\*Entening Extension Phase: only remittors as defined by the DSM-IV criteria of efficacy

\*\*\*O-LES-Q: Quality of Life, Enjoyment and Sattsfaction Questlannaire

Table 4

DAY	minus D7	D0	=>D4
TREATMENTGROUP			
Placebo (PLC)	PLC+PLC	2x(PLC+PLC)	2x(PLC+PC)
PIP - Active / Day 4	PLC+PLC	2x(PLC+PIP (4mg))/d	2x(CIT (10mg)+PIP (4mg))/d
PIP - Active / Day 0	PLC+PLC	2x(CIT (10mg)+PIP (4mg))/d	2x(CIT (10mg)+PIP (4mg))/d
PLC - Active / Day 0	PLC+PLC	2x(CIT (10mg)+PLC)/d	2x(CIT (10mg)+PLC)/d

	Table 5		1. eutoreorgio	a de la contra	   *		××		<b>C</b> × :	××	××	××			c ×		××		×	×										
5			SHIP DAIL	antagontsi	×	-											+			! !.			××	××	ייאיי	××	××	×>	××	
10			ETH8	11 entagorita	ř	-											T:						-							
			ST SMIZE	ortal enterports	×	-	××	×	÷	¢×	××	××			¢×;	-	×		×	×										
15		,_	BLUB. BHIZE	riegorisi entaporisi	×	-	4	×××		÷			-		×				×	-						-				
			SHIA1	entagonis	×	- -	××	**				××	Li.	: :	×				×	-			-			**		- • •		
20		S.	1 12	infibitor agorts	×	-	***	*:* 	(+×+)		× ×	×.×	×	1					*	:										
		· 6	RIMA - MAGA'S MAGE	reuplake infebto	×	-						××	×							×	:		-			-				-
25		221 26	NDRI' NASSA" R		×	_	ĸ×,		××	×,	к×	××			×				×	×			-						× ×	
30			SDRIT NARITH	1	×	- -	×	××				×	×		×		×××		×	×			+ :			+ ;			××	:-
		ś	<u> </u>		×	-	. <u>;</u> ;.	××	<b>:</b> -	<b>∤-</b> ∤ .	×	××		-			××		×	×			+	-	•	H	-		××	
35		COMBO	SHTZATO4" AMAGOTA1 + CNS CORDOMA SHTZATO4" AMAGOTA1 + CNS CORDOMA		×	- }-	Ï	**	××	Ĭ		**			×				×	×		Ì		T		Ï		İ		
			DV2FF		$\frac{\parallel}{\parallel}$														+	_		+						1		}
40		NEOKCAMENT	6HTZA/D4	on the same	×		×	××	××	××	(×)	××	×	××	××	××	××	××	××									××	××	
45				)   				E Buog	Tagos	E sopo	i i				a page	II.	Y L		La you		DER				5	ğ		ander or	P S	
					nowloveredu	क्ष्म् (क्ष्म् क्षितिविधिक्ष	endaly disarders psychotic disorders	esting dhorde morbred syndrom	excheding Pain De facilibus dis	discount and center identity disorders	aloco disorden	adjustment disorder mputae control disorder	pervesive divelopment disorders attention-deficit disorders	Snggive betwektur disorde substance-related disorde	personathy disorde cting medical conditio	methodial behavior	aveaved contration of project	Identity problem phase of the problem	econemic related to obuse or negle	BANDBONDE	DOMENTABLESON	Atthebase Orania	eutstance Arduced portisting demonta	demonta due to HIV disease	demants due to hand traums demants due to Penthaco Chamson	D Huntingan 0		ereral medical (1) Islang emrestic d	The Ingelment disord other capables disords	IRAKKWSONIDIBEABE
50		: 1068		MEDICAL INDICATION	ĸĎĬŝŎŀĸŎ₽ĄŴĬŖĹŅĸŗŨĸŎŁŖŖŶĬĸĠĮĘĸŎŶŔŎĸĬŊŹŚŖĘĠŨĸŶĬŔĸ	MINOW.COGHTIVE MENTALGESCROERS(SEE[SEERDISCOM	:		somotokom disorders (excluding Pain Disordes factitious disorder	Borust and		-	ASSAUGE .	and and	personality disorde psychological factors effecting medical carditio				problems ref	ALC: Velocities	телетический поставляющий подписа		eubstance-fro	5	demonto de	demonte du	omentis duo to C.	difference de de la companie made, de production de la companie del companie del companie de la	ше соди	
		BEE OLOSSARY HEREJNDER		KE	PROMINICANULA	V.COGNETIVE M			Ę						a de la companya de l					***************************************										
55		. פבב סרכ			* BISON	OK														PACKET.	1									

<ul><li>45</li><li>50</li><li>55</li></ul>		40	35	30		25	20		15		10		5	
езсивами некельова	asinadin			8	4	3	ę				şi	21		
		SHTZADs' Aveagon	Artigorial *CHS compound											
	BHT2A / De- Antagorisi		SHI' (agus) a	trosesse brain corcentrators of 8-HT*	Submires P	MG-	echyline pepide	MCH*-receptor	NF Apprile	O.R.		OPCH NC	3-e2 eroca	S mode
NEGICAL INDICATION						╫								
яртясяре в\W(ТУДАНЬУРБЯЦУЛЮДЕ и ОТОН ОХЗЯЕ DUID) ПОМ	×		×	×	×	×	×	×	×	×	×	*	ľ	*
MONCOGATIVE MENTANDIBORDE PRICEPERANDISS 457	_ [	<b>-</b>	_	-	_	-	L	_	_			-		
appace prom	×		××	××	××	××	* *	××	××	××	××	* * * *	××	××
Tapony Days	×		×	×	×	×			×	×	*	×	×	x x
(wheel his granders) resident metalense	××		××	x'x	××	××	**	××	××	××	××	××	××	***
brittous deorders desorters e deorders	××		××	××	* *	× ×	×	*>	×	**	) - ; - 2¢ : 3	×		
season and gende therein, decreases	××		**	×'>	ж, х	i de	() (i)	c)x()		( × )	(×:	(×)	<;×	× ×
returnent decrease	×			dec)	c/×	. ×		< ;×.	××	××	××	××	* *	××
report puncturing expensed	d×:		×	×	×	 ×	XX	×.	×	×	×	×	×.	×
Legion projections express	××								i					
Laport Alphaned	ĸ×		××	××	×.×.	××	* *	* *	××	××	**	××	××	××
physical teams a such particle or district and particle or district and particle or district and particle or district and	××					: :			;-;-		 			
Authorities and	××		××	×	×	×	×	×	×	*	⊹;.		*	×
megad Apado	××		*	×.	×	×				×	×	*	×	×
method on to sound	×								:			-		
Cardia o agree of opposit suspend			× .	×	×	*	×	×	×	×	×	×	×:	×
LAS NATARES SECRETARIOS DE CONTRACTOR DE SAN DESCRICER.		_	*	×	*	×	×	×	×	*	×	×	*	×
Chrystal Care and the control of the		-												
Athene General		+							*				.,	
exhittence-induced perioding dementia						,		4-4-	: ;		j.			
personal victorial designation of the personal designation									÷ :-					
dumenta due to head insure dementa due to Portingo Disease						*								
dementie due to Hundryton Closses						;	CH							-
persect of the board of the board of the company of the board of the b						;. !	×××							
ervestic deorders due to a persent medical condition authorization of seasons are also deorders	××					-	35(1)							
mid cognitive imprimentation and an experimentation of sections.	* *						ciae:							
						,							,	1
Season and the season							-							

SEE CLOSSAGY HEREUNDER	TANKARIA		53		Ç.,	Ę	ঞ		11.	,	÷″	; ;		
	ONON	COUBO										$\ $		
		SHTZA.D4"-Amagonial	ist +CNS compound											
	S-HT2A / Der Antagonita		GABA-B- entagental	vonsrophe rin	ploge	Actipase A2 hm at	algme cac aptor a	euttonemid e 53	Sxveth perceatic hormone	SON. DZ-	- supposts	entage NK3	factoria ratio	CB1
MEDICAL INDICATION								Ħ						
BDISORDERDWINNSHIGHERV/HOE NOT CONDYSECUTOR TOWN	×		,	*	,	  -  -	  -				   ,			
NOW SCOOM IN CHARLE MY AND IS ON DEPONSATIONAL STATES OF THE STATES OF T		+				+	†	+		+	+	+	1	
respond to come			****	3		×	×	X		×	×	×	*	×
samon frame					< ×	× ×	××	×	××	××	×	* * *	××	××
endrosh grites	××		××	××	××	××	××							
cometations disorders (as dualing Pain Disorder)	×		* >	×>	×	*>	) ()*()		*	×	×	×	*	×
dascettre decreed	(×)		( × )	d×;	< ×	< ×	**		* ×	* ×	××	* * * *	××	××
reduced guines receipt on a laborate	×		* ×	K X	××	××	××	×	×	×	×	×	×	×
edus ment decrees impées contro decrees	*   *		××	××	××	××	××	××	××	××	××	××	× ×	××
pervette development decretes	××					×	×	×	×	-	×	×	×.	×
despire behaviore decides especial decides	××				×	××	××	××	××	××	×××	×> ×>	×	×>
trebroit of the process and the control and conditions and the conditions and the conditions and the conditions and the conditions are conditions.	××		×	×	*	×	×	××	××	* *		(x) (x)	( )( ) 	(×)
matropring and account tell and and account tell and account tell acco	××							××	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	×		фф фф	(x)	()×()
breat and breat opens	××		* *	××	××	××	××	××	××	××	×××			×××
Identity problem phase of the problem,	×		- 1 -					×.	×	*	 	×	×.	×
ecademic problems problems related to the se or neglect	××		×	×	×	×	*	×	×	×		×	×.	*
REGROSSING		_				×	×		×	<u> </u>		×	*	×
SIJUBOS MUNICON TON			ı											
						×	×	×	×	×	×	×	×	×
According to the second of the										-				
a brevail of Mind and a bostomb														: :
demants due to has d'earme						-	-			:				:::
Opmenta due lo Partmon Disesse Opmenta due lo Partmon Disesse											-			
demont a due to Pict. Disease						+ 1		* !			<i>-</i> . <i>:</i>	:		
company or such that it is a general made of such that the such desiration of such desiration of suc	×													:
enthalance-induced purels ting arressed of scribes mild cognitive impairment discribes	××	1	• •					-   -						
other cog ristve d'ecréers	×	-												
PASTINS ON DESTRUCTION OF THE PASTINS ON THE PASTINS ON THE PASTIN												×		$\overline{\vdots}$

<i>50 55</i>		40	35		30	25		20		15		10		5	
HEED OSSIVEN WINDSHIP	4(21)(2)(2)		5	¥.	in.	Ş	i) i		· ·						
	QQ Q	•оноэ					$\left  \cdot \right $	$\left\  \cdot \right\ $	$\left\{ \left[ \right] \right\}$			$\left  \cdot \right $	$\  \ $		
	<u></u>	SHT2AD4*Anuportsi +CAB compound	CAB compound												
	SHTZWDF		AMPA' receptor	GAB4.4°	endopai p	prostagandin Payd	Pydrostmuhn emphe	Lambine coroci recupio	T.	guccortood	O earth	Homonal Pytoli	nest Octor	ġ	manico he
MATERIAL MATERIAL							$\left\{ \right\}$			eyeres moos		DE PROPERTO	100 et a		State of NG
And the state of t	ļ		<del>   </del>			$\prod_{i=1}^{n}$			$\prod$			+	$\parallel$		
MEN NONCONGRESSIVATIONS OF THE PARTY OF THE			+	Š		+	-		Ŧ	*		+	<u>*</u>	<u>*</u>	*
retract boom			×									-	-		1
enjey dsorder	×		××			-									
retroop grips	×		×						+-}						
sometime docts (extend of the Decret	×		××		***************************************						•	×			
bediftes doctors	××		× >												
property of the property of th	×				×	×			***		*		-		
radioch genta	*,		××	×	,		×				•				
and the state of t	í×		< ×								*				
and the second s	* .		×								; . ;				
prefront schedist adquish	×		×				×:		*		×		-		
material designation of the control	××		× ×				×	×	×	*	×				,
psychological factors effecting machal conditions	×		. ×		-			4-				-	-	-	
principaling spectra	××		××				.,.								
Ingraphic buildings			× >										<u> </u>	<u>.</u>	
method Albach	×		< ×								· .				
maybo g et la exarto; maybo g estadose	××														- ;
protein related to design register.	×		×												
SECRETARIA SECRETARIA		_	×												
COGNITIVE DEPOSITION		,				+			; []		; 1				
шудар		L	×												
Altherner Decade			×										×	×	×
CATABOLOGY SECURITY S			××				-						×.5	× ,	× ,
dements due to MV daeme			×										G×.	×	×
deneral out to absure deneral density of the contract			× ×				.,		. }				×	* .	×
demonts due to Hurtington Dassace													×	×	××
dements due to Countrale des la Pict. Duesse dements des la Countrales, sons Duesses			×.×										×	×	×
ements dearden das to a general medical condition	×		×										××	* *	××
substruction persisting emestic decolor	×,		×								} - }		×	×	×
and the control of th	×		< ×		÷	-			-		+	~: <u>`</u>	×	*	×
									, ,						
ביים ביים ביים ביים ביים ביים ביים ביים						-			×	×				×	

ACTIONAL HIDEAN HOREATHOR REQUIRING RECORD AND ACTION TO A SECOND ACTION TO A SECOND ACTION A	A44204101  A442024101  X X X X X X X X X X X X X X X X X X X	ACONGO American Ameri	Ministrative compound predict record product appoint	nd Amber age of the Amber and Amber	25 Control of Control	X X X X X X X X X X X X X X X X X X X	X X X		EBW X X X	7 12 12 ×	kedeter   K		S CONTRACTOR X X X M M M M M M M M M M M M M M M M	5-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1	A A
Annewed discosts  Annewed disc	MAMMAM		*******		MAMMAMAMAMAM	××××××××××		XXXXXXXXXXXXXXXX	*******	RARARARARA	শন্ত্রন্ত্রন্ত্রন্ত্রন্ত্রন্ত্রন্ত্রন্ত্	* * * * * * * * * * * * * * * * * * *	ж. ж		

5		SHIZA Autografia - Da Autografia																												
10	-	24 172 Assegned 1 De-Anagonis 1																												
15	, tr	(nài guide) — I bais disflugain fi ush nom	T			*				× ×		* *						-	*. J. *. ( * .; )		* 1	× ×	***		***			***		1
20	ii 19	COX-7				· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·		7-6			*		7 -1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1				4	× ×	•	******************									
25	23 18 18 1 18 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Orthibiae of the milk denouing AZE		×		**************************************	* ************************************		4 - 0				,																	×
30	ii. E	nopile neuroodday jeod (en Det		×																										×
35	1/3 1/3		$\coprod$	×		,				4-1																	*			X , X
40		SH12MOs-Mangeria -CH3 cempound			_										1			  -  -	- П										 7 [	1
45	NEGLECIEN	Angeria		A TYDON		× 34	×	X X	× ·	×			×		**					9630	w page		-	and a			× ×	1		L Tagge
5 <b>0</b>	ete augasan rezresinden		MEDICAL INDICATION	A DISCRIBERTATIVAN UNDERLITIN O EMDITON DITRE EQUIATIO	MARKON COOMINCHENTABOROR DEREYATERADO DE CAR	Sep (Separate )	a aportip operatived	adores las diversos Andre des des des des des des des des des de	theiften de Georgia e de	drawly dead should be been a	de de la constante de la const	and the supplier of	and the state of t	a mpunity Approximated	And March and Andrews	ng tanohaganoa ya shanki	of the state of th	problems release to extres or m.	VACHIO VERIES AND VERIES OF THE SECOND PARTIES OF THE PARTIES OF T	STATE OF STA	destron Attende Chase	editionship on dirig deserts	described to the described to the transfer of	randet best de before de betreet transfer en de best d	demonse due la Martiglan Di-	demonts to Doublethus	envecto decidare des to a quesas acedes conditos adestrandos entrantes en la companiente des des	mld copiles mastered dear	SECTION AND DESCRIPTION OF THE PROPERTY OF THE	I

5	ezcie propionale to i to i to i to i to i to i to i to o to i to o to i to o to i to o to i to o to i to o to i to o to i to o to i to o to i to o to i to o to i to o to i to o to i to o to i to o to i to o to o	
10	Peptor  eceptor  eceptor  Peceptor  Perceptor  Petor  P	sceptor
15	GLOSSARY  GLOSSARY  GLOSSARY  GLOSSARY  CHT = serctionin   Teceptor S-HT   a serctionin   1 receptor S-HT   a serctionin   2 receptor S-HT   a serctionin   2 receptor S-HT   a serctionin   3 receptor S-HT   a serctionin   3 receptor S-HT   a serctionin   3 receptor S-HT   a serctionin   3 receptor S-HT   a serctionin   3 receptor S-HT   a serctionin   3 receptor S-HT   a serctionin   3 receptor S-HT   a serctionin   3 receptor S-HT   a serctionin   3 receptor S-HT   a serctionin   4 receptor S-HT   a serctionin   4 receptor S-HT   a serctionin   4 receptor S-HT   a serctionin   4 receptor S-HT   a serctionin   4 receptor S-T   a rectal or receptor S-T   a receptor S-T   a rectal or receptor S-T   a receptor S-T   a receptor S-T   a receptor S-T   a receptor S-T   a receptor S-T   a receptor S-T   a receptor or receptor S-T   a receptor S-T   a receptor or receptor S-T   a receptor S-T   a receptor S-T   a receptor S-T   a receptor or receptor	V18 = vasopressin 15 re
20		-
25		
30		
35		
40		
45		
50		

		_ Tab	ble 6		
5	COMPANY Server Plan	Metalologo (Bittel-Mors Squtto ClassifityOline Organon Serrol-Synthetto Serrol-Synthetto Estron	Vet, Crade Vet, Crade EtC Premocancia Sorver EvC Premocancia Vets Vets Premocancia Premocancia Premocancia Premocancia Premocancia	Authoroca Authoroca Authoroca Authoroca Authoroca Authoroca Bushing Sorvet Sorv	layer Lucitod / Forest Laboratories Lucitod / Forest Laboratories Lucitod / Forest Laboratories Petro Deb Petro Deb Anory Anor
	OOSE RANGE 25 to 50mg daily wateream	150mg to 450mg 20mg to 60mg dally 1 to 2mg dally warrown	calicown	(app fung a g (app fung a g (a	8 b king dah 20 p king dah 3 b sting dah 40 b libing dah 30 b sting
20	COMPOUND Therefore	interación  Racción (controlled reseas formuscon, cros-de)  gestime  Kalspolan (1998)	WHO (1820 known as OPC-1432) meterrassforme (180 known all geno share) all genotesporme all	PRIX.COCO.  OPERATOR POTRIES  NATION  NATION  NATION  NATION  NATION  NATION  NATION  SELECTION  SE	Identification  Interface of In
<i>25</i>	MAIN INDICATIONS skni Antary skni Antary	Accession Areign B Coperation Areign B Coperation Areign B Coperation B Coperation B Coperation B Coperation Annual B Coperation Areign F Annual B Coperation Areign F Annual B Coperation Areign B Coperation	ibn ibn f Aratin Lion f Aratin Lion f Aratin Lion f Aratin Lion f Aratin Tri Disease		
35	PHARMACOLOGICAL PROFILE SHT inspida enhance Matter profil	in in Attaca SHITA agrid HITA agrid HITA agrid SHITA agrid HITA agrid HITA agrid	SHI'I, gone SHI'I, gone	S-HTIA agraema S-HTIA artagorial S-HTIA artagorial S-HTIB artagorial S-HTIB artagorial S-HTIB artagorial S-HTIB artagorial S-HTIB artagorial S-HTIB artagorial S-HTIB artagorial	Acceptance in mitter  Acceptance in mitter
45	nr. PN. PROF.	5 3 3 3 3 3 3		3.3.3.3.3.3.3.3.3.3.3.3.3.3.3.3.3.3.3.	등 등 등 등 등 등 등 등 등 등 등 등 등 등 등 등 등 등 등
50	AC. GROUP (see overview herounder) Notestational Institute Systems Monominage Institute Systems	DIOCK princell villaging		Montaminergic Trementies Spainns Montaminergic Trementies Spainns Montaminergic Trementies Spainns Montaminergic Trementies Spainns Montaminergic Trementies Spainns Montaminergic Trementies Spainns	Esciatory Anties Acti System Aderosiro Transmitte System Monoemberge, Trensmite System Monoemberge, Trensmite Systems Monoemberge, Trensmite Systems

5	COMPANY	Noven Phermaceuticats	Marachen	I hard themsen death	Saroh Symptotics	Memory Pharmacauticats	Newton Pharmaceudosts	Seroft-Synthelatio	GlacoSmith@ha	Misuosa Hama	Differen		Merck	Novarts Pharmaceuticats	Pitza	Abboti	AstraZeneco	Astracenece	Johnson & Johnson Pharmacourters	Pitter	GbroSnttHOne	Nauroctine Bosolences	Pitze	One Alter Some	्रमी pathani	Schoy			2		,	National treating on Unit Abuse	Peter	School Plants	GlandSmtMthre	Attod	EAD Pharmacoulicats		Color	Conde	Center	North Permana first	MuRes. trst. Pharm. Bochern (CZ)
10	DOSE RANGE	: ::	28 to 300 to 600.		uthoun			untrown	- 45 - 14 - 14 - 14 - 14 - 14 - 14 - 14	for a particular of the			20 to 120mg daily	, 100 to 800mg datly	20 to 60mg daily		Accord deay	industria	6 to 80mg dally	undurban				. uncupar		ustrown							4 to Yamo daliv	4.6 to 13.6mg daily	0.75 to 24mg daily								
. 20	COMPOUND	methytheritate transformal system	Aziened	1(50228	:		safmanda	\$2	J462/35	Johnston	rdecarb	vattecouth	durkund	S X X X	parecoup	JABT-963	AMORE	AAG GRI	R121918 -		723620	NBCM041	Course (8)	DAGASI	emisapide	Dispured	PO 54691	BSF-201640	PO 58491	BSF-201640	PO SONO	e Charita	eumerdada	rotgotine CDS (Once-e-Clay Transdemati Patch)	expirate MCL (controlled-release formulation)	cabergaine	safzolan	D empende D estro	2 × 308	was:	105205	bromodisting	alapido
<i>25</i>	MAIN INDICATIONS	AQ+O	Abremera Usesse	Female Sexual Distinction	Depression / Anderly	Abhelmer's Disease	Pertonon's Disease	Schizophorta	Abbelmer's District	Petr	Path	Path	Path	Pein	7.EF	Petr	and a	Depression	Depression / Anciety	Depression / Andery	Depression	Depression / Andery	Oppression / Analety	Cocarne Dependence	Schizophenta	Contraction Department	Cocatre Dependence				Constant Department	Pertinents Deases	Partengori's Disease	Partoson's Osease, Early and Advanced	Partinsor's Osease Resdass Leg	Cocane Depardence	Perforgor's Disease	Pertingent Dears	Pertensor's Disease, Connected	Decression / Antiery			
35	PHARMACOLOGICAL PROFILE	emphotemine	emfeld soundthe-infoller	drogon raceon modulato	19 bota 3 actenoreceptor agonési	20 Cettum Crevnel Modulator	Catchin Craved Modulator	Carnabold reognor aragonisa	23 challes unites enhances	C.2 hibbits	X.2 Intiblior	COX-2 Inhibitor	COX-2 InhOsitor	COX-2 Intellige	District of the Control of the Contr	COX-order of course (CNC) control (CNC) cont	COX-bribility of the order document (CNODs)	F1 antagorist	CRF1 artagonist	CRF1 entagoritsi	F1 antagonts1	COST BROOMS!	ORF I prizonts	D1 receptor egorisi	D2 receptor entagontsi	DO internation	entogonist	D3 antagontst	03 entagonist	US antagorist	DA uniaha intititiva	DA uctelo errector	dopamine agontst	dopanime agonisi	doparrêne eportst	Sacin america	coperare aports	docume sports	donarmine scorist	doparume aponisi	doparnina agorist	dopanime aports!	dopanina agorisi
40	nr. PH. PROF.	(6)		18 87	19 bd	200	3	21 Car	7 2	8	8	8	88	318	3 8	38	8	8	8	8	8 8	3 8	5 8	10 LZ	2082	200	8	63	8	E E	MOR	ă	31 000	ege G	900	B	8 1	8	8	98	dop	qab	dep
45 50	PHARMAC. GROUP (see overview hereunder)	Putnessie Mechanisms of Demands of the Articlase Long	- W. M. W.	Endoctino System	Monocontinergic Transmiller Systems	/ Untroom	Manual Contract Contr	Forematic Section	Exclusion Artino Acts System	Enzymatic System						Engmatic System		Endocrine System						Monastrinege Transmitte Systems	Moncominerals Transmitte Systems	Monoaminergic Transmitter Systems					Monophinerale Transmitter Systems		Monoaminergic Transmitter Systems										
55	PHARMAC. GROUP	Petropose Mechanisms of		Endoo	Moncontinents	E C	Management	Form	Erdbby An	Eveyan						Erom		Endoo						Monambege	Moncomineral	Monoaminergic					Monoconinensic		Abnoamment										

1   1   1   1   1   1   1   1   1   1	PHARMAC, GROUP (see overview hereunder)	nr. PM. PROF.	PHARMACOLOGICAL PROFILE	MAIN INDICATIONS	COMPOUND	DOSE RANCE	COMPANY
	Enzymate System	×	ERX activation	Althorne de Cinneau	: †		CONTRACT
	Inhibitory Amino Acid System	2	3ABA scords	Atthebne Co. Disease		Auto Dunos os no	Condiu Phermaceuticats
Signature contention	Inhibitory Amino Acid System		2ABA-A coorts!	harmis		uranown	Delich Sehetu, JPW Nathamarn, 68
Coldad medical	Inhibitory Amino Acid System		3ABA-A modulator	hannel		Amo Duny on o	Lundbeck
Colour measure			LAPA-A an didato		A STATE OF THE PARTY OF THE PAR	Z to 2mg dash	Beprecor.
Other mediates			348A.A.modeter	The second	UOCUPA PREDICTORUMENTO NA MUNICIPATO	10 to Zong dafy	Serroll-Synthelabo
Other measure			3494.4 mo 44000	and the same of th	_ material	10 to Zong delly	OOV / Neurocrine
COURT AND COURTS   COURTS   COURTS   COURTS			JABA. Amoditation	Average	Nagodone -	20mg dally	Indeve
Coldina em selator   Coldina			ABA modular	Month	Zatapton extended debase	tong deby	King Pharmacauticats
Colding in registery			ABA A moduloso	Australia	XP17039		Seprence.
March   Marc			A CONTRACTOR OF THE CONTRACTOR	Anxiety, my souler contractions	51.65.1498		Senoil-Synthetabo
Month   Mont			UABA-A ITO GIABION	In sorm la	CP-7 30,330 (NOD 96-3)		Neurosen
10   Column   Colum			GASA-A mo dufator	Insomis	MOD 96-3		Metropen
10			3ABA.A modulator	Anxiety	Odinacion	to to filme delle	700
1	Inhibitory Arrino Acid System	8	GABA-B entrgonist	Depression / Anxiety	AVE 728	inheren	
39   Approximate transport integrates   Accessing Department   Acc	Neurotrophic System	37	Statical Line Derived Memotrophic Factor	Partinson's Disease	3500		S. A.
10 (Outern transport   Author   Autho	Endocrine System	R	glucocarticold synthesis inhibitor	Cocaine Dependence		£ 2000	S Duy
10 G R 4 12 grows   10 G	Excitatory Amino Acid System	Ē	Shitamate receptor entergorist	Anglety	1 1141740		restoris institute on Orug Abuse
Cit Autgoods	Other / Unknown	9	PCR modulation	Decreesion / do int.	01301		Elley
Continue	Endocrine System	-	-A entegorist	dence sains (neutrolis)		-	Roche
Common			19 antenonist	Develope	A CONTRACTOR OF THE CONTRACTOR	South 1200mg daily	Corcept
Demond September   Committee	Monosmin engle Trensmitter Systems	2	43 Antonovial	Alebate A Process	CKC 0461/24630	unknown	Organon
1			3 Antomonia	District of the second	A81-239		Abbot
Particular Scholares	Endocrine System	1	D. A. Charles	ALTHURACIO CO DESCRIP			Abbott
			Principal Statement	PAGE THE PAGE OF SANCTORNS	draspirence Impletiers retradol 0.020 mg to blets	ees formula	Berlea Laboratories
Communication of the control of th			Angelonia Consultation	Perior & Serutal Dystynction	female tastocky one perch		Proctor & Gemble Pharmaceuticals
Character   Char			The second secon	нетепелятие Вунфоте	a yrighelic conjugated entropen A	O. Sing of ally	Bert Leboratories
Principal Scholarce   Principal Scholarce			TOTAL SCOTISTICS	Female Servel Dystunction	tastostarone gei		Slo Santa Pharmaceudes h
Hemmonia Schalatures   Ferral & Sea and Distriction   Histograms Pointenance			Omoral Substance	Female Se zuel Dysfunction	tastostare get		Calbany Pharmacondicate
Permantal Substances   Farmer's Sea and Distriction   Permantal State			formonal Substance	Fernal e Se rue al Dystunction	me Or file sto sterone		Abust Photos codesh
Particular   Par			formonal Butstance	Female Seruel Dystunction	estrocensime Dydestosterone		Section 1
A   Forcesse beth concentration of S411   Digestable   Accident   Digestable			tormonal Substance	Female Serust Dystunction	testostacone banadarmai ancav		2000
Processe beth concentrations of S-471   Digitalization (Acadety 1971)   Processe beth concentrations of S-471   Digitalization (Acadety 1971)   Processe beth concentrations of S-471   Digitalization (Acadety 1971)   Processe beth concentration of S-471   Digitalization (Acadety 1971)   Processe beth concentration (Acadety 1971)   Processe beth concentration of S-471   Digitalization (Acadety 1971)   Processe beth concentration (Acadety 1971)   Processe between	Moncemblegic Transmitter Bysiems	\$	ncrease brein concentrations of 5-4-T	Depression / Andety	ICW 6035		9000
Processe bein concernet action of 5407   Digestation (Action)   199 183			Acresse brein concentrations of 5-407	Degration / Antiety	PAI THE		
Excessible being conserves born of S-FT   Department of Transmiss   Transmis			votesse brein concentrations of 5-4-(T	Decreasing / An date	100 00		
1   1   1   1   1   1   1   1   1   1			Acresse brain concentrations of 3-417	Depression / An delv	Temperatur		
Chicago of the rate (better to the converting staym in table)   Desire   Chicago   C	Endocrine System	150	Creasing insufficensity (IV	Attheirs 's Planes	and the same of the same		,
Company   Comp	Enzymate 8 jetsm	9	thibitor of the mixed lineans times family	Darking Cineses	Organization management	_	GlasoSmith Kilne
1   1   1   1   1   1   1   1   1   1	Enzymate 8 yetem	-	tarletain-1 bets converting enzyme inhibitor	Pain		- CHINDRE	Cephaton
6	Monoamin ergic Transmitter Systems	484	wodosa	Pertinent's Change		-	Avente
10   10   10   10   10   10   10   10	Other / Unknown	9	bid-DNA Complex	Defineda's Classes	of or other contracts of the contract of the c	unturown	TEVA Pharmaceuscats USA
10   10   10   10   10   10   10   10	Monoamin ergit: Transmitter Systems	2	MO reuctable Indiblate	Cocales Described	CAZ 134818		Votents
1 M.O.G is suit Officepate tembler   1000	Monoaminergic Transmitter Bystems		MO resultable inhibitor	4000	The same		National Institute on Drug Abese
1	Monoarraherate Trensmitter Systems	-	MAO. A. P. CA.O. Descriptor interior.	Current	acro cult		Meuro Se ench
MACO   Packbox   Macon   Mac	Monoarth erole Transmitter Systems	165	MO.A tenthine	December 1		May von	Shire Pharmacaudical Development
Succession   Participate   Succession   Su			AOB MANING	Contraction	eategains)		Somer set
State   Stat			140 B Law III	Parchipon is seeds		6 to 1 Oray delly	Amerin Phermecauticets
2) WANCE of propose a middle of the control of th	Monage and Proposition Contract		CACAG INICIAIN	Partmoon's Disease		1 to 2 mg delly	TEVA Pharma caudicats USA / Lund
15   MCA respite integrated   Digestion   Anderly   MCA   1844	Culture interest of the contract of the contra		AC-6 re-uptate multiplion	Partingon's Cinesso			Newton Pharmaceuticats
State State	Pepadergic Iransmiller Syttem	=	IC4 entegoris ts	Depression / Andety	MCL0129		Tabbo
Communication   Communicatio	Peptidergie Transmitter System	\$	CH receptor antagonist	Ospression	SNAP-7941		cheart.
State Burnist contains   Depression   Ancient   Approximation   State Burnist contains   Approximation   App	Endocrine System	28	referentin receptor agordal	haorente	Real Parts	ent town	Total Control
St June agost   June		=	elatoriti receptor agonda	Degression / Anglety	Assimatediae	No. of Contract of	7
SS   Invites 0 to effects 0 i NGF   Azzenim of Disease   Subjection   1 to 2 my day	Exchalory Antho Acid System	169	tauf agorisi	Ansiety	10002001		Service
Stilluptustrick tecopies particle gootest   Authorises (2P)   Superior (US)   Substitution (US)   Substi	Meurobophic System	155	inter the effects of NGF	Atthetre de Manage			Prescient
	Excitatory Amino Acid System	185	Weenfile recentive partial accords	Afternoon ( 10) Channe (10)	- Authorities	To Z mg datay	Serol-Symblebo
MATE   ACT	Monasminergic Transmitter Systems	ŝ	48	Personalization (40 detail	author and a second a second and  UTRADIEN	Delichi Selyeku	
Department of the Control of the Con			EV EV	ADAD	emercons.		Patron
ACCOUNTY (50,000 15,000			187			40 to 100mg dally	E119,
Objected Analety (SAA 13200			194	The Care of the Ca	And the second of the	6 to 1 2mg dealy	Prince
ODE THE STATE OF T				The state of the s	1350 88		Cless Smith ICline
			401	LOUIS BELLEVILLE	(SPA 75200		Abbott

5	COMPANY	Openin	Caros autodina	Schetto-Plant	Sandis whetho	Coragene	Sepracor	Abbott	Senct Syrbetatio	Sanctics yntheir to	Senson Manual	Lundbert / Forest Later appries	Lundback / Forest Labor stortes	Lundback / Forest Lator stortes	MPS.	Boehtner-ingeheim Pharmaceutical s	Month Complete	Mediron	Drug Abuse S ctences	Bosen	Lumbach / Forest	Nather traders on Urug Abuse	Meun	Roche / Mem ory Phorm	Roche f Mem ory Pharm	Serions	Patath Technologies	Serono	Lexizia	Landah	Repulpen	VINUS	Nextiled	SendoSynDetato	Charles Programmed Charles	Centates	Attend by Code on One Abres	Roche	Sandil-Synthetabo	Sandary meneral	9	Santyo
10	DOSE RANGE	untinouni mission de la company	Auto wang cany And in todom satisfic	from Burnou a Arr	90 to XXX no daily	•	unthown	4 to 40mg dally	dan die Di	Consider		ZORRO GLIP	20mg Gally	20mg daily			Carpero Carpero		192 to 384mg	•	nethon.					10 to 0 dm ofto dafe			urûnben		und norm	50 to 300 microgramhapteston		untiroms market	con an encound carry					ump dany		
20	СОМРОИМО	ORGAZO	Calcara	ademotive	25,683	nerve growth factor (NGF) gans therapy	· · · · · · · · · · · · · · · · · · ·		Parameter .	# 2 : • · · · · · · · · · · · · · · · · · ·	T				اء	meloritam	but e Remembraner from of Burtharden)		natu anome depot	depot nathasone microcapsulas	demonstra	Cyaracter F. F. F. F. F. F. F. F. F. F. F. F. F.	ND1251	MEM 1917 (R1497)	JACA 1917 (Russ?)	•		bits wheat breather peptide	104-101c		Hacetytu (dhe)		approximation and a second	į	•		Accts (hill	moctobernida	Information		cinosabre	RS 8369
<i>25</i>	MAIN INDICATIONS	Presentation	Parithmen's Oliverson	Parketon's Disease	Schlzoph enla	Azbeimer's Ottobsa	Anably		5	Schlandt ents / IBS / Over active trincities	Arziely	Athemar's Olsasse	Depresa bri	Path	Depassion	Pain	Atheimer's Disease	Path	Acohol/Drug Depandance	Optale/A traffol Dependence	Anery	Schmidt and	Depression	Azhemer's disease		Ads	Female Sexual Dysfunction	Azheiner's Disease	Degrees the (bender diese das)	School's erta	depression (bipolar disorder)			ACTION OF THE SECOND	Apko	Programia	Cocaine Dependence	Depress on / And ety	Depress on / And oby	Decrets on	Depression / And etv	Depress ion / And ety
35	PHARMACOLOGICAL PROFILE	EDSON E	63 neurolm munoshibi Boanda	neuromodulator	65 preurotensky receptor embgorisa	66 NGF (nerve grow th factor)	recoderts acety cholene nec eptor enlaponist	56 introducting egonsts	Standard M	NX amounts	NA/DA entagent st	NAID A entagoni si			MADA antagoni si		GIVSN			#		oodd soorid		PDE4 INNIE			epited	epide	Proceedings & 2 inhibite with consequently served the	Prospholipase A 2 inhibitor with caspase inhi blor activity				Process Organization and Create and Create Co.						RMA		RWA
	ns. P.H. PROF.	16	9	3	199	99	119	99	100		71	Î							2	F			757		2						187	2						129				
50	PHARMAC. GROUP (see overview hereunder)	Menons from Transmiter Systems	Mour olmmungshills System	Adenosine Transmitter System	Peptiderg te Trensmitter System	New crophs System	Exclusiony Amino Acid System	Deather Franch Cons	Dealten's Tenenthy Cetten		Exclutory Amino Acid System				Comments Carles	man o man o			Ecclatory Ambro Acid System	244 444	mark of the Company of the Company		Enzymatic System		Periffen ir Transmitter Section				markle shoulden		Photostops	Endocrine System	S disease and the	Furbation Amps Acid Section				Monoamfrenge Tonsmitter Systems				

5	COMPANY	Synaptic	AstraZenece	Bristol-Alyers Squitte	Johnson & Johnson Phermaceurical		Novarits Pharmaceutosis	Pitro	(e) E)	Semilorio	Amiral Prodesterns	a de la companya de l	British and a section	AstraZenece	Johnson & Johnson Pharmaceutical	Lurdbeck	Movants Pharmacoulcats	Organon	Senoth Synthetabo		Sumbmo	Lundbeck		Sorvice	Serens yrundamo Chedro	Serofi-Symposto	Seroth-Synthetatio	Sendi-Symbotobo	Redoen	Veta Otsuka	Predh	Predix	Sendi Symboths	Boendnge-Ingehelm Pharmaceuticity	λ 8	<b>90</b> 0	200	MONEN	Manual Industrial	Weed	West	E III	Ę,	Wyen	Lundbeck	LUTTURES / VEGYOR		
10	DOSERANGE									untrown						12 to 24mg daily		Omg dealy	undrown						1.5 to Sens deliv	(			natrown	untrown			ruguom ruguom					60 to 300mm della			75 to 300mg defly	40 to GOmg dethy	1.Bmg/tg/day	unthown				
20	COMPOUND	П	2	911		2		£				2	na hamarata (menulas)	Guediapine (umerate (sustained release)							8	31	265			4	ortn	Paramenin		;·							25								8			
25	MAIN INDICATIONS		Questapa		a manda			a zprestone	tpotor Metritainence)				- Const								34413496					SR 5722	susuju	ephans								1	(DOV 21,947								maximon		17 113671	
30		Depression	Schlaphrania	School	Schoolents	Schoophen	Schtrophrenia	Schhopheria	Depression (	Schopheria	Schaphrena	Although Discour	Schmohren	Schaphrents	Schophrent	Schüppberle	Softmohren	Southern	Commence	Schimotrens	Schaphena	Schootrents	Softcophen	Schoolmans	Decression	Depression	Depression	CHEROSTE STATES	Schimpheria	Depression	CAGY.	Denmedon	Schoopheria	Attreamer's C	Depression /	Athemer's o	Depresson	Demestry	Depression / Analety	Depression	Depression / Anxiety	Depression / Anxiety	9	Demaston	Democrator	Demechn	Depression	
35	PHARMACOLOGICAL PROFILE	11 modulation																			SDA				nd messenger beta econtsi	nd messenger beta egonts!	Second messenger beta egonist	Acretic recisional of the second seco	Secretin penchantle inormone	sigma receptor agontst	a receptor agontsi	stone months establish	Signe receptor entagonist.	2	2	2	2 5											
40	nr. PH. PROF.	80 SCT-	W SDW	100	Š	SOA	SDA	NOS SDA	Š	NOS.	5	5	Š	SOA	SOA	Ś	3 8	5	5	Sov	SOA	Š	S .	PAC SON	66 5000	Seco	88	B7 Secret	Secret	Parameter 68	E ST	and a	Sigme	INDIAN 08	9	DAS .	MONS	91 SWR	SMR	SARI	SAR	288	3 3	BUS	BAS.	SMR	SMRI	
45	PHARMAC, GROUP (see overview herounder)	Other / Unknown	acomitto systems																					anconding Sections	encondition Systems			e System		To Acid System		to Acid System		ansmitter Systems				Insmitter Systems										
55	PHARMAC, GROUP (st	Other /	Managarana A																					Athenandrame To	Monoamhergic Transmitter Systems			Endocthe System		Excitatory Amino Acid System		Exchapay Amiro Acid System		Monoanthergic Transmitter Systems				Moroentherdic Transmitter Systems										

5	COMPANY	GtscSmtD#tBna	Lumbech / Forest Laboratories	of patent	of person	Parer	Botvey	Burrath Synthetratio	Fortoam	Velo Osuba	EAD Promoceutoda	Journalnel	Lundbeck	, Mari		Serrol-Cittohermo	Yomenouchi	Mort	Tokech/Autom	Characterine	Pfter	Roche	Gtung-right Chris	Chargement	Greedmenthe	Etter Phermacondocts	Banah Byrahelabo	Johnson Bathwan Phemocrafted	NAX	Operor	Pare	Serofi Synthetabo	Pitre	70.00	Produ Phermanus de ch												
10	DOSE R ANGE		10 to 20mg delly	10 to 40 mg datay			100 to 300mg daily	undurown										40 to 160mg daily								100 to 600mg daily	untrown	CHOCAL	maram	undrown			50 to 600mg daily	desp During of oc													
20	COMPOUND	eugs.		5	emine	l	Pavoxemine controlled refer to	<b>.</b>	egne	13 (etto trosen es OPC-14523)	9643	CAU	Lu X5-138	3.00	dofrecine	chionhe ( e-edenosymethionine	2		6032	T AMERICA	2,721		97789			mide	886	RZZ8060 (me-10A)	parlamental of the second of t	ORO 38479/PHBO	7,460				L												
25	MAIN INDICATIONS				adon / Antiety Succession		(ex	Depression / Arciety Charatha																	-	gardeemide	Depression / Arxiety SR 461							Procession													
<i>30 35</i>	PHARMACOLOGICAL PROFILE	0	Dage	55	Page 1	Depre	Ander	Oppor	Dense	Depre	Depre	Octor	Oppre	2000	Decre	Depre		raceptor (NK1) entegonist	receptor (NOC1) entercelai	receptor (NOC1) emagandas						. !																					
40		E2 83R1	200	1855	SSRI	SSR	BSBI	SSR	1888	SSRI	SSRI	SSRI	SSR.	2 2	SSS	SSRI	8388	93 Substance P	Schebons	Substanc	Sutstanc	Substr	Substituti	Substr	Substa		monthu 80	unknoe	MOUTUM .	and the same	-Christian	D1 V1B an	enpower and	modulation	nhandonamov 00				7	7				6	9 ;	11	
45	verview hereunder)	refitor Systems																La System								5	Den System					Man.	no system		- Care	THE REAL PROPERTY OF THE PARTY		Monographe Transmitte System	Individual Amena Acid System					Meurotrophic System	Neuroment-rophilin System	STIGHTON OF THE ALZWESTED 1 PURE	
55	PHARMAC, GROUP (see overview hereunder)	Monoeminargio Transmitter Systems																Peppenge Transmits System								Other / Undynomin	Oner / Unknown					ищей в ещоориз	pressury Arms Ac		Other / Unitrosia	PLACE CHARGE CONTROL COMPONICO CONTROL	Arriero Acid Transmitter Bystem	More		П	Aderecabs Transmitter Systems	Francisco System	Nerve Cell Function Bystem			Patroperic Mechanisms of Demantia of the Azherner Type Other / Untroden Systems	

#### Examples

#### Example 1: Measuring pKi values of test compounds

- 5 [0130] In Table 1, the pKi values of test compounds are given for each of the dopamine receptors, 5HT receptors, adrenergic receptors and the histamine1 receptor. The affinity of test compounds for the respective receptors has been performed according to conventional procedures known in the art.
  - [0131] An indication "0" means that no affinity has been measured between the test compound and the receptor.
- [0132] The columns displaying the pKi values for the D4 and the 5-HT2A receptor are filled with dark grey. pKi values between 8 and 9 and higher than 9 are represented by light grey boxes.

# Example 2: Foregoing pipamperon-citalopram treatment in major depressive disorder: a placebo and active controlled period finding clinical trial

15 [0133] Table 2 represents the set-up of a clinical trial comprising for treatment groups:

Group Pic - Active / Day 0 represents the group receiving 10 mg citalopram, twice a day, starting the first day (Day 0) of active treatment in the clinical trial. This administration regime is also indicated as the mono therapy.

Group Pip - Active / Day 0 represents the group receiving a combination of 4 mg pipamperon and 10 mg citalopram, twice a day, starting the first day (Day 0) of active treatment in the clinical trial. This administration regime is also indicated as the non-foregoing combo therapy.

Group Pip - Active / Day 4 represents the group receiving 4 mg pipamperon, twice a day, starting the first day (Day 0) of active treatment in the clinical trial, followed by a combination of 4 mg pipamperon and 10 mg citalopram, twice a day, starting the fifth (Day 4) day of active treatment in the clinical trial. This administration regime is also indicated as the foregoing therapy with combination therapy starting after 4 days of active treatment.

Group Pip - Active / Day 7 represents the group receiving 4 mg pipamperon, twice a day, starting the first day (Day 0) of active treatment in the clinical trial, followed by a combination of 4 mg pipamperon and 10 mg citalopram, twice a day, starting the eight (Day 7) day of active treatment in the clinical trial. This administration regime is also indicated as the foregoing therapy with combination therapy starting after 7 days of active treatment.

30

35

45

20

25

[0134] All subjects also undergo a placebo (PLC) run-in therapy, administered during a period of about 7 days before the active treatment starts.

[0135] During daily (D), weekly (W) or monthly (M) visits, several parameters are measured. Under NECT is to be understood: Neuronal E-clinical Trial = Vesalius Expert development for this trial which includes the bottom-up measurement of:

- In- and exclusion-criteria
- Functional status evaluation
- Medical history
- 40 (Pre-)treatment signs & symptoms
  - DSM-IV rules for diagnosis & efficacy
  - HDRS-28 (Hamilton Depression Rating Scale 28 items)
  - Medical resource utilisation
  - Pre-trial & Concomittant medication
  - Drug administration
    - (Serious) Adverse events
    - Admission to the acute and extension phase of treatment
    - Right flow of the trial

### 50 Example 3: combo pipamperon-citalopram: therapeutic use in Major Depression

### Purpose

[0136] Pipamperon (1'-[3-(p-Fluorobenzoyl)propyl]-[1,4'-bipiperidine]-4'-carboxamide), the active ingredient of Dipiperon (Janssen-Cilag B.V), administered to patients in a dose ranging between 8 and 12 mg is claimed via its specific pharmacological properties to be a booster of the antidepressant effect of the selective serotonin re-uptake inhibitor citalopram. Preferably, pipamperon is administered daily at least 4-5 days before administering said antidepressant. The mechanism of boosting of pipamperon has to deal with (i) the selective affinity for the dopamine-4 (D4) receptor

with a pKi value equal to or higher than 8 towards the D4 receptor and less than 8 towards other dopamine receptors, and (ii) the selective affinity for the 5-HT2A receptor with a pKi value equal to or higher than 8 towards the 5-HT2A receptor and less than 8 towards other 5HT receptors. This semi-naturalistic open label study investigated the efficacy and tolerability of the combo pipamperon - citalopramin the treatment of patients with major depression.

**Details** 

5

[0137]

10 Design: Semi-naturalistic i.e. inclusion of every 'natural' patient in an outpatient practice but without concomitant

use of mood enhancing drugs, open label

Control:

No

Phase: Phase IIa - preliminary Proof of Concept

Location:

Belgium - Research Centre ANIMA, Alken

End Points: Medication:

Assessment scale scores, Hamilton Depression Rating Scale 17 items, Reduction, Response, Remission

Exclusion of mood stabilisers, antipsychotics (typical and atypical) and other antidepressants

Subjects

20 [0138]

Туре	No.	Sex	Age
Patients	23	10 male & 13 female	23-80 (mean 47) years

25

[0139] Characteristics: patients had a major depressive disorder according to DSM-IV criteria, with or without a chronic course and a treatment refractory state towards another SSRI then citalogram.

### **Treatments**

PIP-CIT<sup>1</sup> add-on: citalopram from day minus 60-20 - pipamperon from DAY 0

[0140]

35

30

Drug/Treatment	Dose	Route	Frequency	Duration
Pipamperon <sup>1</sup> Citalopram <sup>1</sup>	+ Pip.: 8-12 mg/day - Cit.: 20- 40 mg/day	РО	bid	8 weeks
1. Pipamperon (Pip) ar	nd citalopram (Cit) dosage was adju	sted acco	rding to clinical	response.

40

PIP-CIT<sup>1</sup> fore-going 1-5: pipamperon from day 0 - cital from day 1-5

[0141]

45

Drug/Treatment Pipamperon <sup>1</sup> Citalopram <sup>1</sup>	<b>Dose</b> + Pip.: 8-12 mg/day - 40 mg/day	Cit.: 20-	Route PO	Frequency bid	Duration 8 weeks
1. Pipamperon (Pip	o) and citalopram (Cit) do	sage was a	djusted ac	cording to clinic	al response.

50

PIP-CIT<sup>1</sup> fore-going 6-8: pipamperon from day 0 - citalopram from day 6-8

[0142]

Drug/Treatment Pipamperon <sup>1</sup> Citalopram <sup>1</sup>	Dose + Pip.: 8-12 mg/day - 40 mg/day	Cit.: 20-	Route PO	Frequency bid	Duration 8 weeks
1. Pipamperon (Pip) and citalopram (Cit) dosage was adjusted according to clinical response.					

Results

5

10

15

20

25

30

35

50

#### [0143]

	PIP-CIT add-on	PIP-CIT foregoing	
	After 20-60 DAYS (mean 33) (n = 5)	1-5 DAYS (mean 4) (n =15)	6-8 DAYS (mean 7) (n = 3)
Mean Used Medication			
Pipamperone	9mg/day	10mg/day	11mg/day
Citalopram	30mg/day	26mg/day	30mg/day
Depression scale scores			
HDRS 17-item total score			
baseline	29	23	28
endpoint (week 8)	4	5	11
diminishment at week 8	-25 (+8/-9)	-18 (+8/-8)	-17 (+17/-17)
% reduction at week 8	86 (+14/-12)	80 (+20/-30)	61 (+39/-61)
response <sup>1</sup> at week 8	5 (100%)	15 (100%)	2 (67%)
remission <sup>2</sup> at week 8	4 (80%)	10 (67%)	1 (33%)

[0144] Notably, the results obtained are highly significant since the variability in every group is distributed evenly around the mean.

# Add-on PIP-CIT

[0145] Figure 1 schematically depicts the "add-on" treatment with pipamperon 8-12 (mean 9) mg (bid) after treatment with citalopram 10-20 (mean 30) mg (bid) during 20-60 (mean 33) days (PIPCIT ADD-ON) with HDRS-17. Totalscore is 29 at baseline in MDD in comparison with the standard efficacy of antidepressants in clinical trials according to Khan et al. (2000), in "Symptom Reduction and Suicide Risk in Patients Treated With Placebo in Antidepressant Clinical Trials" (Arch. of General Psychiatry, Vol. 57, April 2000).

[0146] Figure 2 schematically depicts the HDRS-17 change from baseline in the combo pipamperon as "add-on" to citalopram vs SNRI (duloxetine) in Major Depression. Treatment with pipamperon 8-12 (mean 9 mg/day) during 20-60 (mean 33) days after treatment with SSRI (n=5). The SNRI (duloxetine) treatment was 40-120 mg/day (n = 152) according to Goldstein *et al.*, (Clin. Psychiatry, in press).

[0147] Figure 3 schematically depicts the remission rates (HDRS-17 <=7) with the combo pipamperon as "add-on" to citalopram vs SNRI (venlafaxine) vs SSRIs vs placebo in Major Depression. Treatment with pipamperon 8-12 (mean 9 mg/day) during 20-60 (mean 33) days after treatment with SSRI (n=5). Treatment with the SNRI venlafaxine is according to a meta-analysis of Thase et al. (Br. J. Psychiatry (2001) 178:234-241). Treatment with SSRIs is according to a meta-analysis of Thase et al. (Br. J. Psychiatry (2001) 178:234-241). Treatment with placebo is according to a meta-analysis of Thase et al. (Br. J. Psychiatry (2001) 178:234-241).

### Fore-going 1-5 PIP-CIT

[0148] Figure 4 schematically depicts the "fore-going" treatment during 1-5 (mean 4) days with pipamperon 8-12 (mean 10) mg (bid), followed with the combination treatment of pipamperon and citalopram 20-50 (mean 26) mg/day (bid) (PIPCIT FG 1-5) in MDD (HDRS-17 at BL = 23) in comparison with the standard efficacy of antidepressants in clinical trials according to Khan et al. (2000), in "Symptom Reduction and Suicide Risk in Patients Treated With Placebo in

Antidepressant Clinical Trials" (Arch. of General Psychiatry, Vol. 57, April 2000).

[0149] Figure 5 schematically depicts the HDRS-17 change from baseline in the combo pipamperon-citalopram treatment with a "fore-going" treatment of 4 days with pipamperon (10 mg/day) vs SNRI (duloxetine) in Major Depression. Treatment with the combo pipamperon-citalopram with pipamperon 8-12 (mean 10 mg/day) (bid) 1-5 (mean 4) days before treatment with SSRI (n=15). The SNRI (duloxetine) treatment was 40-120 mg/day (n = 152) according to Goldstein et al., (Clin. Psychiatry, in press).

[0150] Figure 6 schematically depicts the remission rates (HDRS-17 <=7) with the combo pipamperon with a "fore-going" treatment of 4 days with pipamperon (10 mg/day) vs SNRI (venlafaxine) in Major Depression. Treatment with the combo pipamperon-citalopram was with pipamperon 8-12 (mean 10 mg/day) during 1-5 (mean 4) days before treatment with the SSRI (n=5). Treatment with the SNRI venlafaxine is according to a meta-analysis of Thase et al. (Br. J. Psychiatry (2001) 178:234-241). Treatment with SSRIs is according to a meta-analysis of Thase et al. (Br. J. Psychiatry (2001) 178:234-241). Treatment with placebo is according to a meta-analysis of Thase et al. (Br. J. Psychiatry (2001) 178: 234-241).

# Fore-going 6-8 PIP-CIT

25

[0151] Figure 7 schematically depicts the "fore-going" treatment during 6-8 (mean 7) days with pipamperon 8-12 (mean 11) mg/day (bid), followed with the combination treatment of pipamperon and citalopram 20-40 (mean 30) mg/day (bid) (PIPCIT FG 6-8) in MDD (HDRS-17 at BL = 28) in comparison with the standard efficacy of antidepressants in clinical trials according to Khan et al. (2000), in "Symptom Reduction and Suicide Risk in Patients Treated With Placebo in Antidepressant Clinical Trials" (Arch. of General Psychiatry, Vol. 57, April 2000).

[0152] Figure 8 schematically depicts the HDRS-17 change from baseline in the combo pipamperon-citalopram treatment with a "fore-going" treatment of 7 days with pipamperon (11 mg/day) vs SNRI (duloxetine) in Major Depression. Treatment with the combo pipamperon-citalopram with pipamperon 8-12 (mean 11 mg/day) (bid) 6-8 (mean 7) days before treatment with SSRI (n=3). The SNRI (duloxetine) treatment was 40-120 mg/day (n = 152) according to Goldstein et al., (Clin. Psychiatry, in press).

#### Comparison "add-on" vs "fore-going"

[0153] Figure 9 schematically depicts a comparison between "fore-going" and "add-on" treatments with pipamperon (8-12 mg/day; bid) and citalopram (20-40 mg/day; bid) in MDD in comparison with the standard efficacy of antidepressants in clinnical trials according to Khan et al. (2000), in "Symptom Reduction and Suicide Risk in Patients Treated With Placebo in Antidepressant Clinical Trials" (Arch. of General Psychiatry, Vol. 57, April 2000).

[0154] Figure 10 schematically depicts a comparison between "fore-going" and "add-on" treatments. In particular, the HDRS-17 change from baseline between "fore-going" and "add-on" treatment with pipamperon (8-12 mg/day; bid) and citalopram (20-40 mg/day; bid) in comparison with the SNRI duloxetine in Major Depression is depicted. Treatment with the combo pipamperon as "add-on" to citalopram, with pipamperon 8-12 mg/day (mean 9 mg/day) 20-60 (mean 33) days after treatment with the SSRI (n=5). Treatment with the combo pipamperon-citalopram, with pipamperon 8-12 mg/day (mean 11 mg/day; bid) 6-8 days (mean 7 days) before treatment with the SSRI (n = 15). Treatment with the combo pipamperon-citalopram, with pipamperon 8-12 mg/day (mean 10 mg/day; bid) 1-5 days (mean 4 days) before treatment with the SSRI (n = 15). The SNRI (duloxetine) treatment was 40-120 mg/day (n = 152) according to Goldstein et al., (Clin. Psychiatry, in press).

[0155] Figure 11 schematically depicts the remission rates (HDRS-17 <=7) in a comparison between "fore-going" and "add-on" treatment with pipamperon (8-12 mg/day; bid) and citalopram (20-40 mg/day; bid) in comparison with the SNRI venlafaxine in Major Depression. Treatment with the combo pipamperon-citalopram was with pipamperon 8-12 (mean 10 mg/day) during 1-5 (mean 4) days before treatment with the SSRI (n = 15). Treatment with the SNRI venlafaxine is acording to a meta-analysis of Thase et al. (Br. J. Psychiatry (2001) 178:234-241). Treatment with pipamperon as "add-on" to citalopram, with pipamperon 8-12 (mean 9 mg/day) during 20-60 (mean 33) days after treatment with SSRI (n = 5). [0156] The intention-to-treat / last-observation-carried-forward analysis showed a high therapeutic efficacy according HDRS 17-item in all the treatment groups. This was especially true for the 'add-on' group probably caused by the longer treatment with an active antidepressant (+33 days). The huge therapeutic effect observed in the 'PIP-CIT 1-5' group present for at a mean dosage of pipamperon of 10 mg per day and administered the first four days of treatment without an active antidepressant, indicates the boosting effect of pipamperon on the SSRI citalopram at an extremely and thus unconventional low dose. Only 1 patient discontinued treatment due to a lost of follow-up.

## **Adverse Events**

[0157]

Side effects (patients)	PIP-CIT add-on After 20-60 DAYS (mean	PIP-CIT foregoing 1-5 DAYS (mean 4) (n=15)	6-8 DAYS (mean 7) (n = 3)
Discontinued treatment	<b>33) (n = 5)</b> 0	0	0
due to adverse events  By system:			
body as a whole	0	0	0
central and peripheral	1 (20%)	4(26.6%)	0
nervous system	, ,	,	
gastrointestinal	1(20%)	5(33%)	2(66.6%)
musculoskeletal	1(20%)	3(20%)	0
psychiatric	0	0	0
respiratory	0	1 (6.6%)	0
skin and appendages	1(20%)	2(13.3%)	1(33.3%)
vascular	0	1(6.6%)	0
urinary	0	1(6.6%)	0

20

5

10

15

[0158] Laboratory parameters, ECG, bodyweight and vital signs were not measured since this was a naturalistic study.

#### **Assessment**

# 25 Outcome

[0159] Efficacy: the 4-day fore-going combo pipamperon 8-12mg/d - citalopram 20-40mg/day is comparable to the add-on combo pipamperon-citalopram.

[0160] Efficacy: the 4-day fore-going combo pipamperon 8-12mg/d - citalopram 20-40mg/day is larger than the 7-day fore-going combo pipamperon 8-12mg/d - citalopram 20-40mg/day.

[0161] Efficacy: the combo pipamperon 8-12mg/d - citalopram 20-40mg/day is larger than the in the art known antidepressants SSRIs.

### **Tolerability**

35

**[0162]** Tolerability: the 4-day fore-going treatment is comparable to the 7-day fore-going combo is comparable to add-on combo pipamperon-citalopram.

[0163] Tolerability: no discontinued treatment due to adverse events.

# 40 Study Messages

[0164] The boosting effect of pipamperon at an extremely unconventional low dose on a SSRI is indicated since the efficacy of the 'add-on' and '4-day fore-going' combo 'pipamperon 8 -12 mg/d - citalopram 20 - 40 mg/day' is in this study as twice higher as known in the art in the treatment of patients with major depression.

[0165] The combo pipamperon-citalopram is generally well tolerated in patients with depression i.e. at least no specific added adverse events were occurring by adding pipamperon at the doses used in the study.

Example 4: combo pipamperon-citalopram: therapeutic use in Obsessive-Compulsive Disorder (OCD).

### 50 Purpose

[0166] Pipamperon (1'-[3-(p-Fluorobenzoyl)propyl]-[1,4'-bipiperidine]-4'-carboxamide), the active ingredient of Dipiperon (Janssen-Cilag B.V), administered to a patient in a dose ranging between 8 and 12 mg is claimed via its specific pharmacological properties to be a booster of the effect of the selective serotonin re-uptake inhibitor citalopram towards OCD. Preferably, pipamperon is administered daily at least 4-5 days before administering said antidepressant. The mechanism of boosting of pipamperon has to deal with (i) the selective affinity for the dopamine-4 (D4) receptor with a pKi value equal to or higher than 8 towards the D4 receptor and less than 8 towards other Dopamine receptors, and (ii) the selective affinity for the 5-HT2A receptor with a pKi value equal to or higher than 8 towards the 5-HT2A receptor and

less than 8 towards other 5HT receptors. This semi-naturalistic open label study investigated the efficacy and tolerability of the combo pipamperon - citalopram in the treatment of patients with OCD.

### **Details**

5

[0167]

Design:

Semi-naturalistic i.e. inclusion of every 'natural' patient in an outpatient practice but without concomitant

use of mood enhancing drugs, open label

10 Control:

No

Phase: Location: Phase IIa - preliminary Proof of Concept Belgium - Research Centre ANIMA, Alken

End Points : Medication:

Assessment scale scores, Yale-Brown Obsessive-Compulsive Scale, Reduction, Remission

Exclusion of mood stabilisers, antipsychotics (typical and atypical) and other antidepressants

**Subjects** 

[0168]

20

25

30

35

40

45

50

15

Туре	No.	Sex	Age
Patients	7	1 male & 7 female	20-63 (mean 33) years

[0169] Characteristics: patients had an obsessive-compulsive disorder according to DSM-IV criteria, with or without a chronic course and a treatment refractory state towards another SSRI then citalogram.

### **Treatments**

PIP-CIT<sup>1</sup> ADD-ON: citalopram from DAY minus 730-60 - pipamperon from DAY 0

[0170]

Drug/Treatment	Dose		Route	Frequency	Duration
Pipamperone <sup>1</sup> Citalopram <sup>1</sup>	+ Pip.: 8-16 mg/day - mg/day	Cit.: 30-80	РО	bid	12 weeks
1. Pipamperone (Pip) and Citalopram (Cit) dosage was adjusted according to clinical response.					

PIP-CIT<sup>1</sup> FORE-GOING 4-6: pipamperon from DAY 0 - citalogram from DAY 4-6

[0171]

Drug/Treatment	Dose	<u></u>	Route	Frequency	Duration
Pipamperone <sup>1</sup> Citalopram <sup>1</sup>	+ Pip.: 8-16 mg/day - mg/day	Cit.: 30-80	РО	bid	12 weeks
1. Pipamperone (P	ip) and Citalopram (Cit)	dosage was a	diusted ac	cordina to clinic	al response.

# Results

[0172]

### PIP-CIT add-on

after 730-60 DAYS (mean 241) (n = 6) 
with mean Cit. 54mg/d and Pip. 11 mg/d

(continued)

	(commode)
·	PIP-CIT foregoing
	4-6 DAYS (mean 5) (n = 2)
	with mean Cit. 60mg/d and Pip. 10mg/
Y-BOCS score	
Baseline	
Total	31
Obsessions	18
Compulsions	13
Endpoint (week 12)	
Total	15
diminishment	-16 (+16/-11)
<b>a.</b> :	
% reduction	53
Obsessions	
total	- 8
diminishment	-10 (+9/-7)
% reduction	57
Compulsions	
total	7
diminishment	-6 (+7/-6)
% reduction	45
% Remission	
YBOCS score ≤8	- 29
BOCS score ≤16	57

[0173] Notably, the results obtained are highly significant since the variability in every group is distributed evenly around the mean.

[0174] Figure 12 schematically depicts the Y-BOCS total score: "fore-going" and "add-on" treatment with pipamperon (8-15 mg/day; bid) and citalopram (30-80 mg/day; bid) in comparison with the SSRI fluvoxamine in OCD. Treatment with the combo pipamperon-citalopram (n = 7). Treatment with fluvoxamine (controlled release) mean 271 mg/day (n = 253) is according to Hollander et al. (2003).

[0175] Figure 13 schematically depicts the Y-BOCS obsession score: "fore-going" and "add-on" treatment with pipamperon (8-15 mg/day; bid) and citalopram (30-80 mg/day; bid) in comparison with the SSRI fluvoxamine in OCD. Treatment with the combo pipamperon-citalopram (n = 7). Treatment with fluvoxamine (controlled release) mean 271 mg/day (n = 253) is according to Hollander et al. (2003).

[0176] Figure 14 schematically depicts the Y-BOCS compulsion score: "fore-going" and "add-on" treatment with pipamperon (8-16 mg/day; bid) and citalopram (30-80 mg/day; bid) in comparison with the SSRI fluvoxamine in OCD. Treatment with the combo pipamperon-citalopram (n = 7). Treatment with fluvoxamine (controlled release) mean 271 mg/day (n = 253) is according to Hollander et al. (2003).

[0177] The intention-to-treat / last-observation-carried-forward analysis showed a high therapeutic efficacy according Y-BOCS total score, obsession and compulsion scores. This indicates the boosting effect of pipamperon on the SSRI citalopram at an extremely and thus unconventional low dose. No patient discontinued treatment.

# Assessment

5

10

15

20

25

30

35

45

55

[0178] Efficacy: the combo pipamperone 8-16mg/d - citalopram 30-80mg/day > the in the art known compounds effective towards OCD (Hollander E, Koran LM, Goodman WK, Greist JH, Ninan PT, et al. A double-blind, placebo-

controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. Journal of Clinical Psychiatry 64: 640-647, Jun 2003 Mount Sinai School of Medicine, New York, New York, USA; Solvay Pharmaceuticals Inc., Marietta, Georgia, USA).

# 5 Study Messages

**[0179]** The boosting effect of pipamperon at an extremely unconventional low dose on a SSRI is indicated since the efficacy of the 'add-on' and 'fore-going' combo 'pipamperon 8-15 mg/d - citalopram 30-80 mg/day' is in this study as twice higher as known in the art in the treatment of patients with obsessive-compulsive disorder.

Example 5: combo pipamperon-citalopram: therapeutic use in Panic Disorder.

#### **Purpose**

10

[0180] Preliminary examination of a "fore-going" and "add-on" treatment with pipamperon and citalopram in comparison with the SSRI in Panic Disorder.

#### Results

[0181] The results are indicated in Figure 15. Figure 15 schematically depicts the CGI-severity score: "fore-going" and "add-on" treatment with pipamperon (8 mg/day; bid) and citalopram (20-40 mg/day; bid) in comparison with the SSRI in Panic Disorder. Treatment with the combo pipamperon-citalopram (n = 3). Treatment with paroxetine is according to the Journal of Clinical Psychiatry (2004) 65: 405-413. Treatment with Sertraline is according to the Journal of Clinical Psychiatry (2004) 65: 405-413.

# Conclusion

[0182] Notably, although a small test group has been used (n = 3), the distribution around the mean is good. It will further be apparent from Figure 15 that the effect of the combo treatment of pipamperon and citalopram is twice as high as the standard treatments with paroxetine or sertraline.

### Example 6: POC process for mayor depressive disorder

[0183] Concept: Combo of the high selective 5-HT2A/D4 antagonist pipamperon with:

35

30

- a compound active towards the Amino Acid Transmitter, Peptidergic Transmitter, Adenosine Transmitter, Endocrine and/ or Enzymatic System;
- a fore-going admission during 4 days of pipamperon;
- a dose of pipamperon of 12 mg/day

40

45

50

[0184] Objectives: Demonstrating that this combo therapy has:

- the potency of being a treatment standard for depression by having an added value of reducing the total score of the Hamilton Depression Rating Scale - 17 items (HDRS-17) after 8 weeks of therapy with a least 20% more than reached with the conventional known antidepressants, i.e. 60% versus 40%. This stands for an added medium demission of 5 points on the total score of the HDRS-17 and by this will be very highly significant since the mean difference in all recent clinical trials between placebo and active treatment is 2.5;
- a more sustained therapeutic effect than the conventional mono therapy by preventing significant more relapses during 48 weeks following the acute treatment; and/or
- a complete neutral safety profile, e.g. there are no more adverse events in the combo therapy then in mono admission
  of the in the combo used antidepressant compound.

[0185] Process: the following different steps were implemented to reach out for these objectives (see also Tables 3 and 4):

55

(1) an naturalistic open label study (n=>20) on a depressive population with a normal variability of medical and psychiatric history, course of depression, earlier and concomitant therapy admitting the golden standard antidepressant citalopram 20-40 mg/day and a dose of 8-12 mg/day of pipamperon in a foregoing, simultaneous or add-on use.

(2) a 16 weeks placebo controlled randomised four armed study of each 36 patients with a mayor depressive disorder admitting:

- from day 0: placebo or pipamperon (PIP) 10 mg/day or an active antidepressant compound or the combination of the last two;
- from day 4: placebo or pipamperon 10 mg/day combined with an active antidepressant compound or an active antidepressant compound without pipamperon.
- By including rigorous control groups (placebo and active comparator; see Tables 3 and 4) this clinical trial is evaluated as a proof of concept of the added value of the combo and the foregoing treatment method since the inclusion/exclusion of:
  - a negative trial, i.e. no significant difference between the placebo and active treatment with the comparator;
  - a failed trial, i.e. no significant difference between the active and the studied treatment i.e. the combo.
  - (3) an active controlled randomised relapse prevention study following the POC trial during another 36 weeks with three arms of each 36 patients which is formed by:
  - continuation of the active mono therapy;
  - randomising the patients with a combo therapy in a group with an active mono therapy and with a continuation
    of the combo treatment.

# 25 Claims

5

15

20

30

40

- 1. Use of pipamperone or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating a mood disorder or anxiety disorder, wherein said pipamperone or a pharmaceutically acceptable salt is to be administered to a patient in a daily dose ranging between 5 and 15 mg of the active ingredient, and wherein a second compound is to be administered simultaneously with, separate from or sequential to said pipamperone to augment the therapeutic effect of said second compound, said second compound is selected from the group consisting of: selective serotonin, nor-adrenaline and dopamine re-uptake inhibitor (SNDRI), selective serotonin and nor-adrenaline re-uptake inhibitor (SNRI) and selective serotonin re-uptake inhibitor (SNRI).
- 2. The use according to claim 1, wherein said pipamperon is to be administered daily at least one day before administering said second compound.
  - 3. The use of pipamperone or a pharmaceutically acceptable salt thereof according to any of claims 1 to 2, wherein said second compound is a selective serotonin, nor adrenaline and dopamine re-uptake inhibitor (SNDRI) compound.
  - 4. The use according to claim 3, wherein said selective serotonin, nor-adrenaline and dopamine re-uptake inhibitor (SNDRI) compound is selected from the group consisting of NS 2330, McN 5652, DOV 216,303 and DOV 21,947, or a pharmaceutically acceptable salt thereof.
- 5. A pharmaceutical composition comprising (a) pipamperone, and (b) a selective serotonin, nor-adrenaline and dopamine re-uptake inhibitor (SNDRI) compound, as a combined preparation for simultaneous, separate or sequential use for treating the underlying emotion dysregulation of mental disease or disorder which is chosen from the group consisting of mood disorders and anxiety disorders, wherein said pipamperone is to be administered to a patient in a daily dose of between 5 and 15 mg of the active ingredient.
  - 6. The pharmaceutical composition according to claim 5, wherein said selective serotonin, nor-adrenaline and dopamine re-uptake inhibitor (SNDRI) compound is selected from the group consisting of NS 2330, McN 5652, DOV 216,303 and DOV 21,947, or a pharmaceutically acceptable salt thereof
- 7. The use of pipamperone or a pharmaceutically acceptable salt thereof according to any of claims 1 to 2, wherein said second compound is a selective serotonin and nor-adrenaline re-uptake inhibitor (SNRI) compound.
  - 8. The use of pipamperone or a pharmaceutically acceptable salt thereof according to claim 7, wherein said selective

serotonin and nor-adrenaline re-uptake inhibitor (SNRI) compound is selected from the group consisting of venlafaxine, tomoxetine, tandamine, talsupram, talopram, nefazodone, milnacipran, LY 113.821, duloxetine, desvenlafaxine and amoxapine, or a pharmaceutically acceptable salt thereof.

- 9. The use of pipamperone or a pharmaceutically acceptable salt thereof according to claim 8, wherein said venlafaxine, or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof, is to be administered in a daily dose ranging between 75 and 300 mg of the active ingredient.
  - 10. The use of pipamperone or a pharmaceutically acceptable salt thereof according to claim 8, wherein said tomoxetine, or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof, is to be administered in a daily dose ranging between 0.475 and 3.8 mg/kg of the active ingredient.

10

15

20

25

30

40

45

- 11. The use of pipamperone or a pharmaceutically acceptable salt thereof according to claim 8, wherein said milnacipran, or a pharmaceutically acceptable salt thereof, is to be administered in a daily dose ranging between 50 and 200 mg of the active ingredient.
- 12. The use of pipamperone or a pharmaceutically acceptable salt thereof according to claim 8, wherein said duloxetine, or a pharmaceutically acceptable salt thereof, is to be administered in a daily dose ranging between 40 and 60 mg of the active ingredient.
- 13. A pharmaceutical composition comprising (a) pipamperone and (b) a selective serotonin and nor-adrenaline re-uptake inhibitor (SNRI) compound as a combined preparation for simultaneous, separate or sequential use for treating the underlying emotion dysregulation of mental disease or disorder which is chosen from the group consisting of mood disorders and anxiety disorders, wherein said pipamperone is to be administered to a patient in a daily dose of between 5 and 15 mg of the active ingredient.
- 14. The pharmaceutical composition according to claim 13, wherein said selective serotonin and nor-adrenaline re-uptake inhibitor (SNRI) compound is selected from the group consisting of venlafaxine, tomoxetine, tandamine, talsupram, talopram, nefazodone, milnacipran, LY 113.821, duloxetine, desvenlafaxine and amoxapine, or a pharmaceutically acceptable salt thereof,
- **15.** The pharmaceutical composition according to claim 14, wherein said venlafaxine, or a pharmaceutically acceptable salt thereof, provided in a unitary dose of between 75 and 300 mg of the active ingredient:
- 35 16. The pharmaceutical composition according to claim 14, wherein said tomoxetine, or a pharmaceutically acceptable salt thereof, is provided in a unitary dose of between 0.475 and 3.8 mg/kg of the active ingredient.
  - 17. The pharmaceutical composition according to claim 14, wherein said milnacipran, or a pharmaceutically acceptable saft thereof, is provided in a unitary dose of between 50 and 200 mg of the active ingredient.
  - 18. The pharmaceutical composition according to claim 14, wherein said duloxetine, or a pharmaceutically acceptable salt thereof, is provided in a unitary dose of between 40 and 60 mg of the active ingredient.
  - 19. The use of pipamperone or a pharmaceutically acceptable salt thereof according to any of claims 1 to 2, wherein said second compound is a selective serotonin reuptake inhibitor (SSRI) compound.
    - 20. The use of pipamperone or a pharmaceutically acceptable salt thereof according to claim 19, wherein said selective serotonin re-uptake inhibitor (SSRI) compound is selected from the group consisting of YM 992, VPI-013 (OPC-14523), sertraline, paroxetine, LY 214.281, LU AA 21-004, Lu 35-138, litoxetine, ifoxetine, fluvoxamine (controlled release formulation), fluvoxamine, fluoxetine, femoxetine, escitalopram, EMD 68843, cyanodothepine, citalopram, venlafaxine, milnacipran, duloxetine, cericlamine and ademethionine (preferably S-adenosylmethionine), or a pharmaceutically acceptable salt thereof.
- 21. The use of pipamperone or a pharmaceutically acceptable salt thereof according to claim 20, wherein said selective serotonin re-uptake inhibitor (SSRI) compound is uvoxamine (controlled release formulation), or a pharmaceutically acceptable salt thereof, is to be administered in a daily dose ranging between 100 and 300 mg of the active ingredient.
  - 22. The use of pipamperone or a pharmaceutically acceptable salt thereof according to claim 20, wherein said selective

serotonin re-uptake inhibitor (SSRI) compound is escitalopram, and is to be administered in a daily dose ranging between 10 and 20 mg of the active ingredient.

- 23. The use of pipamperone or a pharmaceutically acceptable salt thereof according to claim 20, wherein said selective serotonin re-uptake inhibitor (SSRI) compound is citalopram, and is to be administered in a daily dose ranging between 10 and 40 mg of the active ingredient.
- 24. A pharmaceutical composition comprising (a) pipamperone and (b) a selective serotonin re-uptake inhibitor (SSRI) compound as a combined preparation for simultaneous, separate or sequential use for treating the underlying emotion dysregulation of mental disease or disorder which is chosen from the group consisting of mood disorders and anxiety disorders, wherein said pipamperone is to be administered to a patient in a daily dose of between 5 and 15 mg of the active ingredient.
- 25. The pharmaceutical composition according to claim 24, wherein said selective serotonin re-uptake inhibitor (SSRI) compound is selected from the group consisting of YM 992, VPI-013 (also known as OPC-14523), sertraline, par-oxetine, LY 214.281, LU AA 21-004, Lu 35-138, litoxetine, ifoxetine, fluvoxamine (controlled release formulation), fluvoxamine, fluoxetine, femoxetine, escitalopram, EMD 68843, cyanodothepine, citalopram, venlafaxine, milnacipran, duloxetine, cericlamine and ademethionine (preferably s-adenosylmethionine), or a pharmaceutically acceptable salt thereof.
  - 26. The pharmaceutical composition according to claim 25, wherein said fluvoxamine (controlled release formulation), or a pharmaceutically acceptable salt thereof, is provided in a unitary dose of between 100 and 300 mg of the active ingredient.
- 25 27. The pharmaceutical composition according to claim 25, wherein said escitalopram, or a pharmaceutically acceptable salt thereof, is provided in a unitary dose of between 10 and 20 mg of the active ingredient.
  - 28. The pharmaceutical composition according to claim 25, wherein said citalopram, or a pharmaceutically acceptable salt thereof, is provided in a unitary dose of between 10 and 40 mg of the active ingredient.

# Patentansprüche

5

10

20

30

35

40

- 1. Verwendung von Pipamperon oder eines pharmazeutisch verträglichen Salzes davon zur Darstellung von einem Medikament für die Behandlung einer affektiven Störung oder einer Angststörung, wobei das Pipamperon oder ein pharmazeutisch verträgliches Salz an einen Patienten in einer täglichen Dosis zu verabreichen ist, die in einem Bereich zwischen 5 und 15 mg des Wirkstoffes liegt, und wobei eine zweite Verbindung gleichzeitig mit, getrennt von oder aufeinanderfolgend zu dem Pipamperon zu verabreichen ist, um die therapeutische Wirkung von der zweiten Verbindung zu verstärken, und wobei die zweite Verbindung ausgewählt ist aus der Gruppe bestehend aus: selektive Serotonin-, Noradrenalin- und Dopamin-Wiederaufnahmehemmer (SNDRI), selektive Serotonin- und Noradrenalin-Wiederaufnahmehemmer (SNRI).
  - 2. Verwendung nach Anspruch 1, wobei das Pipamperon täglich zu verabreichen ist, mindestens einen Tag vor der Verabreichung der zweiten Verbindung.
  - Verwendung von Pipamperon oder eines pharmazeutisch verträglichen Salzes davon nach einem der Ansprüche 1 oder 2, wobei die zweite Verbindung eine selektive Serotonin-, Noradrenalin- und Dopamin-Wiederaufnahmehemmer- (SNDRI-) Verbindung ist.
- 4. Verwendung nach Anspruch 3, wobei die selektive Serotonin-, Noradrenalin- und Dopamin-Wiederaufnahmehemmer-(SNDRI-) Verbindung ausgewählt ist aus der Gruppe, die aus NS 2330, McN 5652, DOV 216,303 und DOV 21,947 oder einem pharmazeutisch verträglichen Salz davon besteht.
- 5. Pharmazeutische Zusammensetzung, die (a) Pipamperon und (b) eine selektive Serotonin-, Noradrenalin- und Dopamin-Wiederaufnahmehemmer- (SNDRI-) Verbindung als ein Kombinationspräparat umfasst, zur gleichzeitigen, getrennten oder aufeinanderfolgenden Verwendung bei der Behandlung der zugrunde liegenden Emotionsdysregulation der seelischen Erkrankung oder Störung, welche ausgewählt ist aus der Gruppe, die aus affektiven Störungen und Angststörungen besteht, wobei das Pipamperon an einen Patienten in einer täglichen Dosis von

zwischen 5 und 15 mg des Wirkstoffes zu verabreichen ist.

- Pharmazeutische Zusammensetzung nach Anspruch 5, wobei die selektive Serotonin-, Noradrenalin- und Dopamin-Wiederaufnahmehemmer- (SNDRI-) Verbindung ausgewählt ist aus der Gruppe, die aus NS 2330, McN 5652, DOV 216, 303 und DOV 21,947 oder einem pharmazeutisch verträglichen Salz davon besteht.
- Verwendung von Pipamperon oder eines pharmazeutisch verträglichen Salzes davon nach einem der Ansprüche 1 oder 2, wobei die zweite Verbindung eine selektive Serotonin- und Noradrenalin-Wiederaufnahmehemmer- (SNRI-) Verbindung ist.
- 8. Verwendung von Pipamperon oder einem pharmazeutisch verträglichen Salz davon nach Anspruch 7, wobei die selektive Serotonin- und Noradrenalin-Wiederaufnahmehemmer- (SNRI-) Verbindung ausgewählt ist aus der Gruppe, die aus Venlafaxin, Tomoxetin, Tandamin, Talsupram, Talopram, Nefazodon, Milnacipran, LY 113.821, Duloxetin, Desvenlafaxin und Amoxapin oder einem pharmazeutisch verträglichen Salz davon besteht.
- 9. Verwendung von Pipamperon oder einem pharmazeutisch verträglichen Salz davon nach Anspruch 8, wobei das Venlafaxin oder eine Pro-Drug oder ein aktiver Metabolit davon, oder ein pharmazeutisch verträgliches Salz davon, in einer täglichen Dosis zu verabreichen ist, die in einem Bereich zwischen 75 und 300 mg von dem Wirkstoff liegt.
- 20 10. Verwendung von Pipamperon oder einem pharmazeutisch verträglichen Salz davon nach Anspruch 8, wobei das Tomoxetin oder eine Pro-Drug oder ein aktiver Metabolit davon, oder ein pharmazeutisch verträgliches Salz davon, in einer täglichen Dosis zu verabreichen ist, die in einem Bereich zwischen 0,475 und 3,8 mg/kg von dem Wirkstoff liegt.
- 25 11. Verwendung von Pipamperon oder einem pharmazeutisch verträglichen Salz davon nach Anspruch 8, wobei das Milnacipran oder ein pharmazeutisch verträgliches Salz davon in einer täglichen Dosis zu verabreichen ist, die in einem Bereich zwischen 50 und 200 mg von dem Wirkstoff liegt.
- 12. Verwendung von Pipamperon oder einem pharmazeutisch verträglichen Salz davon nach Anspruch 8, wobei das Duloxetin oder ein pharmazeutisch verträgliches Salz davon in einer täglichen Dosis zu verabreichen ist, die in einem Bereich zwischen 40 und 60 mg von dem Wirkstoff liegt.
  - 13. Pharmazeutische Zusammensetzung, die (a) Pipamperon und (b) eine selektive Serotonin- und Noradrenalin-Wiederaufnahmehemmer- (SNDRI-) Verbindung als ein Kombinationspräparat umfasst, zur gleichzeitigen, getrennten oder aufeinanderfolgenden Verwendung bei der Behandlung der zugrunde liegenden Emotionsdysregulation der seelischen Erkrankung oder Störung, welche ausgewählt ist aus der Gruppe, die aus affektiven Störungen und Angststörungen besteht, wobei das Pipamperon an einen Patienten in einer täglichen Dosis von zwischen 5 und 15 mg des Wirkstoffes zu verabreichen ist.
- 40 14. Pharmazeutische Zusammensetzung nach Anspruch 13, wobei die selektive Serotonin- und Noradrenalin-Wiederaufnahmehemmer- (SNRI-) Verbindung ausgewählt ist aus der Gruppe, die aus Venlafaxin, Tomoxetin, Tandamin, Talsupram, Talopram, Nefazodon, Milnacipran, LY 113.821, Duloxetin, Desvenlafaxin und Amoxapin oder einem pharmazeutisch verträglichen Salz davon besteht.
- 45 15. Pharmazeutische Zusammensetzung nach Anspruch 14, wobei das Venlafaxin oder ein pharmazeutisch verträgliches Salz davon in einer Einheitsdosis von zwischen 75 und 300 mg des Wirkstoffs bereitgestellt wird.
  - **16.** Pharmazeutische Zusammensetzung nach Anspruch 14, wobei das Tomoxetin oder ein pharmazeutisch verträgliches Salz davon in einer Einheitsdosis von zwischen 0,475 und 3,8 mg/kg des Wirkstoffs bereitgestellt wird.
  - 17. Pharmazeutische Zusammensetzung nach Anspruch 14, wobei das Milnacipran oder ein pharmazeutisch verträgliches Salz davon in einer Einheitsdosis von zwischen 50 und 200 mg des Wirkstoffs bereitgestellt wird.
  - 18. Pharmazeutische Zusammensetzung nach Anspruch 14, wobei das Duloxetin oder ein pharmazeutisch verträgliches Salz davon in einer Einheitsdosis von zwischen 40 und 60 mg des Wirkstoffs bereitgestellt wird.
  - Verwendung von Pipamperon oder eines pharmazeutisch verträglichen Salzes davon nach einem der Ansprüche
     oder 2, wobei die zweite Verbindung eine selektive Serotonin-Wiederaufnahmehemmer- (SSRI-) Verbindung ist.

35

50

55

10

- 20. Verwendung von Pipamperon oder eines pharmazeutisch verträglichen Salzes davon nach Anspruch 19, wobei die selektive Serotonin-Wiederaufnahmehemmer- (SSRI-) Verbindung ausgewählt ist aus der Gruppe, die aus YM 992, VPI-013 (OPC-14523), Sertralin, Paroxetin, LY 214.281, LU AA 21-004, Lu 35-138, Litoxetin, Ifoxetin, Fluvoxamin (Formulierung mit kontrollierter Wirkstofffreisetzung), Fluvoxamin, Fluoxetin, Femoxetin, Escitalopram, EMD 68843, Cyanodothepin, Citalopram, Venlafaxin, Milnacipran, Duloxetin, Cericlamin und Ademethionin (vorzugsweise S-Adenosylmethionin) oder einem pharmazeutisch verträglichen Salz davon besteht.
- 21. Verwendung von Pipamperon oder einem pharmazeutisch verträglichen Salz davon nach Anspruch 20, wobei die selektive Serotonin-Wiederaufnahmehemmer- (SRRI-) Verbindung Fluvoxamin (Formulierung mit kontrollierter Wirkstofffreisetzung) oder ein pharmazeutisch verträgliches Salz davon ist, die in einer täglichen Dosis zu verabreichen ist, welche in einem Bereich zwischen 100 und 300 mg von dem Wirkstoff liegt.
  - 22. Verwendung von Pipamperon oder einem pharmazeutisch verträglichen Salz davon nach Anspruch 20, wobei die selektive Serotonin-Wiederaufnahmehemmer- (SRRI-) Verbindung Escitalopram ist und die in einer täglichen Dosis zu verabreichen ist, welche in einem Bereich zwischen 10 und 20 mg von dem Wirkstoff liegt.
  - 23. Verwendung von Pipamperon oder einem pharmazeutisch verträglichen Salz davon nach Anspruch 20, wobei die selektive Serotonin-Wiederaufnahmehemmer- (SRRI-) Verbindung Citalopram ist und die in einer täglichen Dosis zu verabreichen ist, welche in einem Bereich zwischen 10 und 40 mg von dem Wirkstoff liegt.
- 24. Pharmazeutische Zusammensetzung, die (a) Pipamperon und (b) eine selektive Serotonin-Wiederaufnahmehemmer- (SSRI) Verbindung als ein Kombinationspräparat umfasst, zur gleichzeitigen, getrennten oder aufeinanderfolgenden Verwendung bei der Behandlung der zugrunde liegenden Emotionsdysregulation der seelischen Erkrankung oder Störung, welche ausgewählt ist aus der Gruppe, die aus affektiven Störungen und Angststörungen besteht, wobei das Pipamperon an einen Patienten in einer täglichen Dosis von zwischen 5 und 15 mg des Wirkstoffes zu verabreichen ist.
- 25. Pharmazeutische Zusammensetzung nach Anspruch 24, wobei die selektive Serotonin-Wiederaufnahmehemmer-(SSRI-) Verbindung ausgewählt ist aus der Gruppe, die aus YM 992, VPI-013 (ebenfalls bekannt als OPC-14523), Sertralin, Paroxetin, LY 214.281, LU AA 21-004, Lu 35-138, Litoxetin, Ifoxetin, Fluvoxamin (Formulierung mit kontrollierter Wirkstofffreisetzung), Fluvoxamin, Fluoxetin, Femoxetin, Escitalopram, EMD 68843, Cyanodothepin, Citalopram, Venlafaxin, Milnacipran, Duloxetin, Cericlamin und Ademethionin (vorzugsweise S-Adenosylmethionin) oder einem pharmazeutisch verträglichen Salz davon besteht.
- 26. Pharmazeutische Zusammensetzung nach Anspruch 25, wobei das Fluvoxamin (Formulierung mit kontrollierter Wirkstofffreisetzung) oder ein pharmazeutisch verträgliches Salz davon in einer Einheitsdosis von zwischen 100 und 300 mg des Wirkstoffs bereitgestellt wird.
  - 27. Pharmazeutische Zusammensetzung nach Anspruch 25, wobei das Escitalopram oder ein pharmazeutisch verträgliches Salz davon in einer Einheitsdosis von zwischen 10 und 20 mg des Wirkstoffs bereitgestellt wird.
    - 28. Pharmazeutische Zusammensetzung nach Anspruch 25, wobei das Citalopram oder ein pharmazeutisch verträgliches Salz davon in einer Einheitsdosis von zwischen 10 und 40 mg des Wirkstoffs bereitgestellt wird.

#### Revendications

5

10

15

20

25

30

40

45

50

- 1. Utilisation de la pipampérone ou d'un sel pharmaceutiquement acceptable de celle-ci pour la préparation d'un médicament pour le traitement d'un trouble de l'humeur ou d'un trouble de l'anxiété, dans laquelle ladite pipampérone ou un sel pharmaceutiquement acceptable de celle-ci doit être administrée à un patient sous forme d'un dosage quotidien compris entre 5 et 15 mg de l'ingrédient actif, et dans laquelle un deuxième composé doit être administré simultanément à, séparément de ou séquentiellement à ladite pipampérone pour augmenter l'effet thérapeutique dudit deuxième composé, ledit deuxième composé étant sélectionné parmi le groupe constitué de l'inhibiteur du recaptage de la sérotonine, la noradrénaline et la dopamine sélectif (SNDRI), l'inhibiteur du recaptage de la sérotonine sélectif (SNRI) et l'inhibiteur du recaptage de la sérotonine sélectif (SSRI).
- 2. Utilisation selon la revendication 1, dans laquelle ladite pipampérone doit être administrée quotidiennement au moins un jour avant d'administrer ledit deuxième composé.

- 3. Utilisation de la pipampérone ou d'un sel pharmaceutiquement acceptable de celle-ci selon 1"une quelconque des revendications 1 ou 2, dans laquelle ledit deuxième composé est un composé inhibiteur du recaptage de la sérotonine, la noradrénaline et la dopamine sélectif (SNDRI).
- 4. Utilisation selon la revendication 3, dans laquelle ledit composé inhibiteur du recaptage de la sérotonine, la noradrénaline et la dopamine sélectif (SNDRI) est sélectionné parmi le groupe constitué de NS 2330, McN 5652, DOV 216,303 et DOV 21,947, ou un sel pharmaceutiquement acceptable de ceux-ci.
- 5. Composition pharmaceutique comprenant (a) de la pipampérone, et (b) un composé inhibiteur du recaptage de la sérotonine, la noradrénaline et la dopamine sélectif (SNDRI), en tant qu'une préparation combinée pour une utilisation simultanée, séparée ou séquentielle pour le traitement de la dérégulation des émotions sous-jacente d'une maladie ou d'un trouble mental qui est choisi(e) parmi le groupe constitué de troubles de l'humeur et de troubles de l'anxiété, dans laquelle ladite pipampérone doit être administrée à un patient sous forme d'un dosage quotidien compris entre 5 et 15 mg de l'ingrédient actif.

15

25

35

45

50

55

6. Composition pharmaceutique selon la revendication 5, dans laquelle ledit composé inhibiteur du recaptage de la sérotonine, la noradrénaline et la dopamine sélectif (SNDRI) est sélectionné parmi le groupe constitué de NS 2330, McN 5652, DOV 216,303 et DOV 21,947, ou un sel pharmaceutiquement acceptable de ceux-ci.

- 7. Utilisation de la pipampérone ou d'un sel pharmaceutiquement acceptable de celle-ci selon 1"une quelconque des revendications 1 ou 2, dans laquelle ledit deuxième composé est un composé inhibiteur du recaptage de la sérotonine et la noradrénaline sélectif (SNRI).
  - 8. Utilisation de la pipampérone ou d'un sel pharmaceutiquement acceptable de celle-ci selon la revendication 7, dans laquelle ledit composé inhibiteur du recaptage de la sérotonine et la noradrénaline sélectif (SNRI) est sélectionné parmi le groupe constitué de venlafaxine, tomoxétine, tandamine, talsupram, talopram, néfazodone, milnacipran, LY 113.821, duloxétine, desvenlafaxine et amoxapine, ou un sel pharmaceutiquement acceptable de ceux-ci.
- 9. Utilisation de la pipampérone ou d'un sel pharmaceutiquement acceptable de celle-ci selon la revendication 8, dans laquelle ladite venlafaxine ou un promédicament ou un métabolite actif de celle-ci, ou un sel pharmaceutiquement acceptable de celle-ci, doit être administrée sous forme d'un dosage quotidien compris entre 75 et 300 mg de l'ingrédient actif.
  - 10. Utilisation de la pipampérone ou d'un sel pharmaceutiquement acceptable de celle-ci selon la revendication 8, dans laquelle fadite tomoxétine ou un promédicament ou un métabolite actif de celle-ci, ou un sel pharmaceutiquement acceptable de celle-ci, doit être administrée sous forme d'un dosage quotidien compris entre 0,475 et 3,8 mg/kg de l'ingrédient actif.
- 11. Utilisation de la pipampérone ou d'un sel pharmaceutiquement acceptable de celle-ci selon la revendication 8, dans laquelle ledit milnacipran ou un sel pharmaceutiquement acceptable de celui-ci, doit être administré sous forme d'un dosage quotidien compris entre 50 et 200 mg de l'ingrédient actif.
  - 12. Utilisation de la pipampérone ou d'un sel pharmaceutiquement acceptable de celle-ci selon la revendication 8, dans laquelle ladite duloxétine ou un sel pharmaceutiquement acceptable de celle-ci, doit être administrée sous forme d'un dosage quotidien compris entre 40 et 60 mg de l'ingrédient actif.
  - 13. Composition pharmaceutique comprenant (a) de la pipampérone et (b) un composé inhibiteur du recaptage de la sérotonine et la noradrénaline sélectif (SNRI), en tant qu'une préparation combinée pour une utilisation simultanée, séparée ou séquentielle pour le traitement de la dérégulation des émotions sous-jacente d'une maladie ou d'un trouble mental qui est choisi(e) parmi le groupe constitué de troubles de l'humeur et de troubles de l'anxiété, dans laquelle ladite pipampérone doit être administrée à un patient sous forme d'un dosage quotidien compris entre 5 et 15 mg de l'ingrédient actif.
  - 14. Composition pharmaceutique selon la revendication 13, dans laquelle ledit composé inhibiteur du recaptage de la sérotonine et la noradrénaline sélectif (SNRI) est sélectionné parmi le groupe constitué de venlafaxine, tomoxétine, tandamine, talsupram, talopram, néfazodone, milnacipran, LY 113.821, duloxétine, desvenlafaxine et amoxapine, ou un sel pharmaceutiquement acceptable de ceux-ci.

- 15. Composition pharmaceutique selon la revendication 14, dans laquelle ladite venlafaxine ou un sel pharmaceutiquement acceptable de celle-ci, est pourvue sous forme de dosage unitaire compris entre 75 et 300 mg de l'ingrédient actif.
- 5 16. Composition pharmaceutique selon la revendication 14, dans laquelle ladite tomoxétine ou un sel pharmaceutiquement acceptable de celle-ci, est pourvue sous forme de dosage unitaire compris entre 0,475 et 3,8 mg/kg de l'ingrédient actif.
- 17. Composition pharmaceutique selon la revendication 14, dans laquelle ledit milnacipran ou un sel pharmaceutiquement acceptable de celui-ci, est pourvu sous forme de dosage unitaire compris entre 50 et 200 mg de l'ingrédient actif.
  - 18. Composition pharmaceutique selon la revendication 14, dans laquelle ladite duloxétine ou un sel pharmaceutiquement acceptable de celle-ci, est pourvue sous forme de dosage unitaire compris entre 40 et 60 mg de l'ingrédient actif.
- 15 19. Utilisation de la pipampérone ou d'un sel pharmaceutiquement acceptable de celle-ci selon l'une quelconque des revendications 1 ou 2, dans laquelle ledit deuxième composé est un composé inhibiteur du recaptage de la sérotonine sélectif (SSRI).

20

25

30

40

45

50

- 20. Utilisation de la pipampérone ou d'un sel pharmaceutiquement acceptable de celle-ci selon la revendication 19, dans laquelle ledit composé inhibiteur du recaptage de la sérotonine sélectif (SSRI) est sélectionné parmi le groupe constitué de YM 992, VPI-013 (OCP-14523), sertraline, paroxétine, LY 214.281, LU AA 21-004, Lu 35-138, litoxétine, ifoxétine, fluvoxamine (formulation à libération contrôlée), fluvoxamine, fluoxétine, fémoxétine, escitalopram, EMD 68843, cyanodothépine, citalopram, venlafaxine, milnacipran, duloxétine, cériclamine et adéméthionine (de préférence S-adénosylméthionine), ou un sel pharmaceutiquement acceptable de ceux-ci.
  - 21. Utilisation de la pipampérone ou d'un sel pharmaceutiquement acceptable de celle-ci selon la revendication 20, dans laquelle ledit composé inhibiteur du recaptage de la sérotonine sélectif (SSRI) est la fluvoxamine (formulation à libération contrôlée), ou un sel pharmaceutiquement acceptable de celle-ci, et doit être administrée sous forme d'un dosage quotidien compris entre 100 et 300 mg de l'ingrédient actif.
  - 22. Utilisation de la pipampérone ou d'un sel pharmaceutiquement acceptable de celle-ci selon la revendication 20, dans laquelle ledit composé inhibiteur du recaptage de la sérotonine sélectif (SSRI) est l'escitalopram, et doit être administré sous forme d'un dosage quotidien compris entre 10 et 20 mg de l'ingrédient actif.
- 23. Utilisation de la pipampérone ou d'un sel pharmaceutiquement acceptable de celle-ci selon la revendication 20, dans laquelle ledit composé inhibiteur du recaptage de la sérotonine sélectif (SSRI) est le citalopram, et doit être administré sous forme d'un dosage quotidien compris entre 10 et 40 mg de l'ingrédient actif.
  - 24. Composition pharmaceutique comprenant (a) de la pipampérone et (b) un composé inhibiteur du recaptage de la sérotonine sélectif (SSRI), en tant qu'une préparation combinée pour une utilisation simultanée, séparée ou séquentielle pour le traitement de la dérégulation des émotions sous-jacente d'une maladie ou d'un trouble mental qui est choisi(e) parmi le groupe constitué de troubles de l'humeur et de troubles de l'anxiété, dans laquelle ladite pipampérone doit être administrée à un patient sous forme d'un dosage quotidien compris entre 5 et 15 mg de l'ingrédient actif.
    - 25. Composition pharmaceutique selon la revendication 24, dans laquelle ledit composé inhibiteur du recaptage de la sérotonine sélectif (SSRI) est sélectionné parmi le groupe constitué de YM 992, VPI-013 (également connu comme OPC-14523), sertraline, paroxétine, LY 214.281, LU AA 21-004, Lu 35-138, litoxétine, ifoxétine, fluvoxamine (formulation à libération contrôlée), fluvoxamine, fluoxétine, fémoxétine, escitalopram, EMD 68843, cyanodothépine, citalopram, venlafaxine, milnacipran, duloxétine, cériclamine et adéméthionine (de préférence S-adénosylméthionine), ou un sel pharmaceutiquement acceptable de ceux-ci.
    - 26. Composition pharmaceutique selon la revendication 25, dans laquelle ladite fluvoxamine (formulation à libération contrôlée), ou un sel pharmaceutiquement acceptable de celle-ci, est pourvue sous forme de dosage unitaire compris entre 100 et 300 mg de l'ingrédient actif.
    - 27. Composition pharmaceutique selon la revendication 25, dans laquelle ledit escitalopram, ou un sel pharmaceutiquement acceptable de celui-ci, est pourvu sous forme de dosage unitaire compris entre 10 et 20 mg de l'ingrédient

actif.

<b>2</b> 8	8. Composition pharmaceutique selon la revendication 25, dans laquelle ledit citalopram, ou un sel pharmaceutique ment acceptable de celui-ci, est pourvu sous forme de dosage unitaire compris entre 10 et 40 mg de l'ingrédient acti
10	
15	```
20	
25	
30	
35	
40	
45	
55	




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11




Figure 12




Figure 13




Figure 14




Figure 15

#### REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

### Non-patent literature cited in the description

- GROSS, J. J.; MUNOZ, R. F. Emotion regulation and mental health. Clinical Psychology: Science and Practice, 1995, vol. 2, 151-164 [0004]
- MENNIN, D.S.; HEIMBERG, R. G.; TURK, C. L.; FRESCO, D. M. Applying an emotion regulation framework to integrative approaches to generalized anxiety disorder. Clinical Psychology: Science and Practice, vol. 9, 85-90 [0004]
- LINEHAN, M. M. Cognitive-behavioral treatment of borderline personality disorder. The Guilford Press, 1993 [0004]
- GRATZ, K. L.; ROEMER, L. Multidimensional assessment of emotion regulation and dysregulation: development, factor structure, and initial validation of the Difficulties in Emotion Regulation Scale. Annual meeting of the Association for Advancement of Behavior Therapy, November 2001 [0004]
- Journal of Psychopathology and Behavioral Assessment, March 2004, vol. 26 (1 [0004]
- O'MALLEY, K. L.; HARMON, S.; TANG, L.; TODD, R. D. The rat dopamine D4 receptor: sequence, gene structure, and demonstration of expression in the cardiovascular system. New Biol., 1992, vol. 4, 137-46 [0004]
- SVENSSON, T. H.; MATHÉ, A. A. et al. Monoaminergic Transmitter Systems, Biological Psychiatry. John Wiley & Sons, Ltd, 2002, 45-66 [0004]
- D. L. FELDPAUSCH et al. The Journal of Pharmacology and Experimental Therapeutics, July 1998, vol. 286 (1), 497-508 [0004]
- X. XIBERAS; J.L. MARTINOT. The British Journal of Psychiatry, 2001, vol. 179, 503-508 [0005]
- SMITA PATEL et al. The Journal of Pharmacology and Experimental Therapeutics, 1997, vol. 283 (2), 636-647 [0005]
- KRAMER, M.S. et al. Arch. Gen. Psychiatry, December 1997, vol. 54 (12), 1080 [0005]
- J.E. LEYSEN. 5-HT2 Receptors. Current Drug Targets CNS & Neurological Disorders, 2004, vol. 3, 11-26 [0006]
- D.A. GUTMAN; C.B. NEMEROFF et al. Neuroendocrinology, Biological Psychiatry. John Wiley & Sons, Ltd, 2002, vol. 99 [0007]

- E. A. YOUNG. Mineralocorticoid Receptor Function in Major Depression. Arch Gen Psychiatry, January 2003, vol. 60, 24-28 [0007]
- S. M. STAHL. Newer Antidepressants and Mood Stabilizers, Essential Psychopharmacology. University Press, 15 June 2000, vol. 265 [0008]
- S. M. STAHL. Classical Antidepressants, Serotonin Selective and Noradrenargic Reuptake Inhibitors, Essential Psychopharmacology. University Press, 15 June 2000, vol. 233 [0008]
- S. M. STAHL. Essential Psychopharmacology, Depression and Bipolar Disorders. University Press, 15
  June 2000, vol. 151 [0009]
- S. M. STAHL. Essential Psychopharmacology, Depression and Bipolar Disorders. University Press, 15
  June 2000, vol. 152 [0009]
- ESIRI, M.M. The basis for behavioural disturbances in dementia. J. Neurol. Neurosurg. Psychiatry, 1996, vol. 61 (2), 127-130.2 [0072]
- Pharmaceutics and Pharmacy Practice. J.B. Lippincott Company, 1982, 238-250 [0098]
- ASHP Handbook on Injectable Drugs. 1986, 622-630 [0098]
- KHAN et al. Symptom Reduction and Suicide Risk in Patients Treated With Placebo in Antidepressant Clinical Trials. Arch. of General Psychiatry, April 2000, vol. 57 [0145] [0148] [0153]
- THASE et al. Br. J. Psychiatry, 2001, vol. 178, 234-241 [0147] [0147] [0147] [0150] [0150] [0155]
- KHAN et al. Symptom Reduction and Suicide Risk in Patients Treated With Placebo in Antidepressant Clinical Trials. Arch. of General Psychiatry, April 2001, vol. 57 [0151]
- GOLDSTEIN et al. Clin. Psychiatry [0154]
- A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. HOL-LANDER E; KORAN LM; GOODMAN WK; GRE-IST JH; NINAN PT et al. Journal of Clinical Psychiatry. Solvay Pharmaceuticals Inc, June 2003, vol. 64, 640-647 [0178]
- Journal of Clinical Psychiatry, 2004, vol. 65, 405-413 [0181] [0181]